<SEC-DOCUMENT>0001213900-21-065682.txt : 20211216
<SEC-HEADER>0001213900-21-065682.hdr.sgml : 20211216
<ACCEPTANCE-DATETIME>20211216160549
ACCESSION NUMBER:		0001213900-21-065682
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20211216
DATE AS OF CHANGE:		20211216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-251973
		FILM NUMBER:		211497856

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea152498-424b5_chinapharma.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS SUPPLEMENT </B></FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Filed pursuant to Rule 424(b)(5) </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(To Prospectus dated January 21, 2021) </FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>File No. 333-251973 </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;<B>CHINA PHARMA
HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$5,000,000 of Shares of Common Stock Underlying</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5% Convertible Promissory Note due 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
covers the issuance of $5,000,000 worth of our common stock, par value $0.001, issuable to an institutional accredited investor (&ldquo;Noteholder&rdquo;)
upon the conversion or redemption of $5,000,000 aggregate principal amount of 5% convertible promissory note (the &ldquo;Note&rdquo;)
due 2023 and interest accrued thereon. Pursuant to the terms of the securities purchase agreement for the sale and issuance of the Note,
we are hereby registering the shares of common stock issuable upon the conversion of the Note for the amount of $5,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Noteholder <FONT STYLE="background-color: white">may
redeem all or any part of the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one
(121) days from the day the purchase price of the Note is delivered from the </FONT>Noteholder <FONT STYLE="background-color: white">to
the Company upon three trading days&rsquo; notice, in cash or converting into shares of the Company&rsquo;s common stock at a price equal
to 85% multiplied by the lowest daily VWAP during the ten (10) trading days immediately preceding the applicable redemption conversion,
subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure
to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor&rsquo;s
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registration of the issuance
of the shares hereunder does not necessarily mean that the Noteholder will convert the Note into common stock. We will not receive any
of the proceeds from the issuance of the shares to the Noteholder, but we agreed to pay certain registration expenses relating to the
registration of such shares with the U.S. Securities and Exchange Commission, or the SEC. See &ldquo;Plan of Distribution&rdquo; elsewhere
in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our common
stock trades on the NYSE American under the symbol &ldquo;CPHI.&rdquo; The last reported sale price of our common stock on the NYSE American
on December 15, 2021 was $0.43 per share.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in these securities
involves certain risks. Our entity that offers securities under this prospectus is not a Chinese operating company but a holding company
incorporated in the Nevada. The Nevada holding company has no material operations of its own. We conduct a substantial majority of our
operations through our operating entity established in the People&rsquo;s Republic of China, or the PRC. </B>&nbsp;<B>Additionally, we
are subject to certain legal and operational risks associated with our PRC subsidiary&rsquo;s operations in China. PRC laws and regulations
governing our current business operations are sometimes vague and uncertain, and therefore, these risks may result in a material change
in our PRC subsidiary&rsquo;s operations, significant depreciation of the value of our common stock, or a complete hindrance of our ability
to offer or continue to offer our securities to investors. Recently, the PRC government initiated a series of regulatory actions and statements
to regulate business operations in China with little advance notice, including cracking down on illegal activities in the securities market,
enhancing supervision over China-based companies listed overseas using variable interest entity structure, adopting new measures to extend
the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. Since these statements and regulatory actions
are new, it is highly uncertain how soon legislative or administrative regulation making bodies will respond and what existing or new
laws or regulations or detailed implementations and interpretations will be modified or promulgated, if any, and the potential impact
of such modified or new laws and regulations will have on our daily business operation, the ability to accept foreign investments and
list on an U.S. or other foreign exchange.&nbsp;Please carefully consider the &ldquo;Risk Factors&rdquo; contained in, or incorporated
by reference into, this prospectus, including the &ldquo;Risk Factors&rdquo; beginning on page S-3 of this prospectus supplement, for
a discussion of the factors you should consider carefully before deciding to purchase these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to
the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>The date of this prospectus
supplement is December 16, 2021</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#S_002"><FONT STYLE="font-size: 10pt">FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-iii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#S_003"><FONT STYLE="font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_004">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: center">S-3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_005">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: center">S-6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_006">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: center">S-7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_007">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="text-align: center">S-8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_008">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center">S-8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_010">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: center">S-9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#S_009">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center">S-9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; width: 95%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle; width: 5%">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">ABOUT OUR COMPANY</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">4</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">THE SECURITIES WE MAY OFFER</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF COMMON STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">7</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">8</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">9</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">DESCRIPTION OF RIGHTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">11</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">12</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">13</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_001"></A>ABOUT THIS PROSPECTUS
SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
prospectus supplement is a supplement to the accompanying prospectus that is also a part of this document. This prospectus supplement
and the accompanying prospectus, dated January 21, 2021, are part of a registration statement on Form S-3 (File No. 333-251973) that we
filed with the Securities and Exchange Commission, or the SEC, utilizing a &ldquo;shelf&rdquo; registration process. Under this shelf
registration process, we may offer and sell from time to time in one or more offerings the securities described in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
document is in two parts. The first part is this prospectus supplement, which describes the securities we are offering and the terms of
the offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference
into the accompanying prospectus. The second part is the accompanying prospectus, which provides more general information, some of which
may not apply to the securities offered by this prospectus supplement. Generally, when we refer to this &ldquo;prospectus,&rdquo; we are
referring to both documents combined. To the extent there is a conflict between the information contained in this prospectus supplement,
on the one hand, and the information contained in the accompanying prospectus or any document incorporated by reference therein, on the
other hand, you should rely on the information in this prospectus supplement. We urge you to carefully read this prospectus supplement
and the accompanying prospectus, together with the information incorporated herein and therein by reference as described under the heading
&ldquo;Where You Can Find Additional Information,&rdquo; before buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You
should not consider any information in this prospectus supplement or the accompanying prospectus to be investment, legal or tax advice.
You should consult your own counsel, accountants and other advisors for legal, tax, business, financial and related advice regarding the
purchase of any of the securities offered by this prospectus supplement. You should assume that the information in this prospectus supplement
and the accompanying prospectus is accurate only as of the date on the front of the document and that any information we have incorporated
by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus
supplement and the accompanying prospectus or any sale of a security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made
to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies
of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading
&ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_002"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
prospectus supplement, the accompanying prospectus and the documents that we have filed with the SEC that are incorporated by reference
in this prospectus supplement contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and may involve material risks, assumptions and uncertainties. Forward-looking statements typically are identified by the
use of terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;might,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; and similar words, although some forward-looking
statements are expressed differently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any
forward looking statements contained in this prospectus supplement, the accompanying prospectus and the documents that we have filed with
the SEC that are incorporated by reference in this prospectus supplement are only estimates or predictions of future events based on information
currently available to our management and management&rsquo;s current beliefs about the potential outcome of future events. Whether these
future events will occur as management anticipates, whether we will achieve our business objectives, and whether our revenues, operating
results, or financial condition will improve in future periods are subject to numerous risks. There are a number of important factors
that could cause actual results to differ materially from the results anticipated by these forward-looking statements. These important
factors include those that we discuss under the heading &ldquo;Risk Factors&rdquo; and in other sections of our Annual Report on Form
10-K for the fiscal year ended December 31, 2020, as well as in our other reports filed from time to time with the SEC that are incorporated
by reference into this prospectus supplement and the accompanying prospectus. You should read these factors and the other cautionary statements
made in this prospectus supplement, the accompanying prospectus and in the documents we incorporate by reference into this prospectus
supplement and the accompanying prospectus as being applicable to all related forward-looking statements wherever they appear in this
prospectus supplement or the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus. If
one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements
may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. We
undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_003"></A>PROSPECTUS SUPPLEMENT
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This
summary is not complete and does not contain all of the information that you should consider before investing in the shares of common
stock offered by this prospectus supplement. You should read this summary together with the entire prospectus supplement and the accompanying
prospectus, including our risk factors (as provided for herein and incorporated by reference), financial statements, the notes to those
financial statements and the other documents that are incorporated by reference in this prospectus supplement, before making an investment
decision. You should carefully read the information described under the heading &ldquo;Where You Can Find More Information.&rdquo; We
have not authorized anyone to provide you with information different from that contained in this prospectus supplement. The information
contained in this prospectus supplement is accurate only as of the date of this prospectus supplement, regardless of the time of delivery
of this prospectus supplement or of any sale of our securities. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Unless
the context otherwise requires, references to &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;China Pharma&rdquo;, &ldquo;the Company&rdquo;
or &ldquo;our Company&rdquo; refer to China Pharma Holdings, Inc. and its wholly owned subsidiaries.. &ldquo;China&rdquo; and the &ldquo;PRC&rdquo;
refer to the People&rsquo;s Republic of China.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Organization and Nature of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China Pharma Holdings, Inc.,
a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson
Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;).
China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Onny acquired 100% of the
ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&rsquo;s three former shareholders. The
transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval
for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing
its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired and
continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview &amp; Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are principally engaged
in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence
and high-mortality diseases and medical conditions prevalent in the People&rsquo;s Republic of China (the &ldquo;PRC&rdquo;). All of our
operations are conducted in the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form
of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical
products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National
Medical Products Administration (the &ldquo;NMPA&rdquo;, formerly China Food and Drug Administration, or CFDA) based upon demonstrated
safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&rsquo;s consistency
evaluation of generic drugs had continued to proceed in the third quarter of 2021. The supporting policies from central and provincial
governments have been constantly issued, including polices regarding consistency evaluation for injectable products. We have always taken
the task of facilitating the consistency evaluation as our top priority, and worked on them actively. However, due to the continuous dynamic
changes of the detailed policies, future market, expected investment, and return of investment (&ldquo;ROI&rdquo;) for each drug&rsquo;s
consistency evaluation, the whole industry, including us, has been making slow progress in terms of the consistency evaluation. We have
a product that passed biological equivalents experiments of consistency evaluation in March 2021. We plan to submit application documents
to NMPA in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding-right: 4pt; padding-left: 4pt; border: Black 1.5pt solid; width: 98%">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have taken a more cautious
and flexible attitude towards initiating and progressing any project for an existing product&rsquo;s consistency evaluation and to cope
with the changing macro environment of drug sales in China. On one hand, since &ldquo;4 + 7&rdquo; (refers to 11 selected pilot cities,
including 4 municipalities and 7 other cities) trial Centralized Procurement (&ldquo;CP&rdquo;) activities initiated in 2018, five rounds
of CP activities had been carried out by June 2021, which significantly reduced the price of the drugs that won the bids. On the other
hand, the consistency evaluation has been adopted as one of the qualification standards for participating in the CP activities. As a result,
we need to balance at least the two factors above before making decisions for any products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we continue to
explore the field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed according to the development of
the times, social needs and changes in disease spectrum. According to the Outline of &ldquo;Healthy China 2030&rdquo; issued by Chinese
government in October 2016, the total size of China&rsquo;s health service industry will reach more than RMB 8 trillion by 2020, and RMB
16 trillion by 2030. This industry focuses on people&rsquo;s daily life, aging and disease, pays attention to all kinds of risk factors
and misunderstandings affecting health, calls for self-health management, and advocates the comprehensive care of the entire process of
life. It covers all kinds of health-related information, products and services, as well as actions taken by various organizations to meet
the health needs. We launched Noni enzyme, a natural, Xeronine-rich antioxidant food supplement at the end of 2018, wash-free sanitizers
and masks, in 2020, to address the market needs caused by COVID-19 in China. The impact of COVID-19 has continued. Masks and sanitizers
have become long-time anti-epidemic materials. We have sufficient production capacity for medical masks, surgical masks and KN95 masks,
which meets the personal needs for protection against the epidemic outbreak.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will continue to optimize
our product structure and actively respond to the current health needs of human beings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Trends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a generic drug company,
we are presented with a huge domestic market. We believe that through further upgrades and consistency evaluations, we will be able to
meet the European and American production standards, which will enable us to export our products to overseas markets. In the future, cost
management and control ability will gradually become an important factor in determining the competitiveness of generic pharmaceutical
enterprises. Although price control leads to a decline in the profitability, the CP&rsquo;s winning enterprise has a good chance of achieving
price-for-volume in order to increase its market share and support its continuous innovation transformation. On a separate note, consumption
upgrading in China drives the increase of optional consumption. With the improvement of residents&rsquo; quality of life, the healthcare
demand is also changing. We believe that there is a large number of unmet demands in comprehensive healthcare and Internet healthcare
sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Office of
the State Council issued &ldquo;<I>Pilot Plan for Marketing Authorization Holders</I>&rdquo; on May 24, 2016, allowing eligible drug research
and development institutions and scientific researchers to become Marketing Authorization Holders (&ldquo;MAH&rdquo;) by obtaining drug
marketing authorization and drug approval numbers from the State Council. This policy uses a management model of separating drug marketing
authorization and drug production licenses, thereby allowing an MAH to produce pharmaceuticals itself or to consign production to other
pharmaceutical manufacturers. This policy not only transitions our production practices to meet the European and United States standards
by separating drug approval and production qualifications, thereby changing the existing model of bundling drug approval numbers to pharmaceutical
manufacturers in China, but also serves as a supplement to the ongoing consistency evaluations policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, demand for pharmaceutical
products is still experiencing steady growth in China. We believe the ongoing generic drug consistency evaluations and reform of China&rsquo;s
drug production registration and review policies will have major effects on the future development of our industry and may change its
business patterns. We will continue to actively adapt to the national policy guidance and further evaluate market conditions for our existing
products, and competition in the market in order to optimize our development strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">.</P>


</div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An
investment in our shares of common stock involves a high degree of risk. Before making any investment decision, you should carefully consider
the risk factors set forth in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein
and therein, including under the caption &ldquo;Risk Factors&rdquo; in our most recent annual report on Form 10-K, as well as in any applicable
prospectus supplement, as updated by our subsequent filings under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These
risks could materially affect our business, results of operation or financial condition and affect the value of our securities. Additional
risks and uncertainties that are not yet identified may also materially harm our business, operating results and financial condition and
could result in a complete loss of your investment. You could lose all or part of your investment. For more information, see &ldquo;Where
You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Substantial uncertainties and restrictions
with respect to the political and economic policies of the PRC government and PRC laws and regulations could have a significant impact
upon the business that we may be able to conduct in the PRC and accordingly on the results of our operations and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business operations conducted
through our wholly owned subsidiaries may be adversely affected by the current and future political environment in the PRC. The Chinese
government exerts substantial influence and control over the manner in which we must conduct our business activities. Our ability to operate
in China may be adversely affected by changes in Chinese laws and regulations. Under the current government leadership, the government
of the PRC has been pursuing reform policies which have adversely affected China-based operating companies whose securities are listed
in the United States, with significant policies changes being made from time to time without notice. There are substantial uncertainties
regarding the interpretation and application of PRC laws and regulations, including, but not limited to, the laws and regulations governing
our business, or the enforcement and performance of our contractual arrangements with borrowers in the event of the imposition of statutory
liens, death, bankruptcy or criminal proceedings. Only after 1979 did the Chinese government begin to promulgate a comprehensive system
of laws that regulate economic affairs in general, deal with economic matters such as foreign investment, corporate organization and governance,
commerce, taxation and trade, as well as encourage foreign investment in China. Although the influence of the law has been increasing,
China has not developed a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects
of economic activities in China. Also, because these laws and regulations are relatively new, and because of the limited volume of published
cases and their lack of force as precedents, interpretation and enforcement of these laws and regulations involve significant uncertainties.
New laws and regulations that affect existing and proposed future businesses may also be applied retroactively. In addition, there have
been constant changes and amendments of laws and regulations over the past 30 years in order to keep up with the rapidly changing society
and economy in China. Because government agencies and courts provide interpretations of laws and regulations and decide contractual disputes
and issues, their inexperience in adjudicating new business and new polices or regulations in certain less developed areas causes uncertainty
and may affect our business. Consequently, we cannot predict the future direction of Chinese legislative activities with respect to either
businesses with foreign investment or the effectiveness on enforcement of laws and regulations in China. The uncertainties, including
new laws and regulations and changes of existing laws, as well as judicial interpretation by inexperienced officials in the agencies and
courts in certain areas, may cause possible problems to foreign investors. Although the PRC government has been pursuing economic reform
policies for more than two decades, the PRC government continues to exercise significant control over economic growth in the PRC through
the allocation of resources, controlling payments of foreign currency, setting monetary policy and imposing policies that impact particular
industries in different ways. We cannot assure you that the PRC government will continue to pursue policies favoring a market oriented
economy or that existing policies will not be significantly altered, especially in the event of a change in leadership, social or political
disruption, or other circumstances affecting political, economic and social life in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, given the PRC
government&rsquo;s significant oversight and discretion over the conduct of our operating subsidiaries&rsquo; business, it may&nbsp;intervene&nbsp;or
influence the operations of our PRC subsidiaries at any time and to exert control over an offering of securities conducted overseas and/or
foreign investment in China-based issuers, which may cause us to make material changes to the operations of our PRC subsidiaries and could
significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of our
securities to significantly decline or be worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse regulatory developments in China
may subject us to additional regulatory review, and additional disclosure requirements and regulatory scrutiny to be adopted by the SEC
in response to risks related to recent regulatory developments in China may impose additional compliance requirements for companies like
us with significant China-based operations, all of which could increase our compliance costs, subject us to additional disclosure requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The recent regulatory developments
in China, in particular with respect to restrictions on China-based companies raising capital offshore, may lead to additional regulatory
review in China over our financing and capital raising activities in the United States. In addition, we may be subject to industry-wide
regulations that may be adopted by the relevant PRC authorities, which may have the effect of limiting our service offerings, restricting
the scope of our operations in China, or causing the suspension or termination of our business operations in China entirely, all of which
will materially and adversely affect our business, financial condition and results of operations. We may have to adjust, modify, or completely
change our business operations in response to adverse regulatory changes or policy developments, and we cannot assure you that any remedial
action adopted by us can be completed in a timely, cost-efficient, or liability-free manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 30, 2021, in response
to the recent regulatory developments in China and actions adopted by the PRC government, the Chairman of the SEC issued a statement asking
the SEC staff to seek additional disclosures from offshore issuers associated with China-based operating companies before their registration
statements will be declared effective. On August 1, 2021, the China Securities Regulatory Commission stated in a statement that it had
taken note of the new disclosure requirements announced by the SEC regarding the listings of Chinese companies and the recent regulatory
development in China, and that both countries should strengthen communications on regulating China-related issuers. We cannot guarantee
that we will not be subject to tightened regulatory review and we could be exposed to government interference in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compliance with China&rsquo;s new Data Security
Law, Measures on Cybersecurity Review (revised draft for public consultation), Personal Information Protection Law (second draft for consultation),
regulations and guidelines relating to the multi-level protection scheme and any other future laws and regulations may entail significant
expenses and could materially affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China has implemented or will
implement rules and is considering a number of additional proposals relating to data protection. China&rsquo;s new Data Security Law promulgated
by the Standing Committee of the National People&rsquo;s Congress of China in June 2021, or the Data Security Law, took effect in September
2021. The Data Security Law provides that the data processing activities must be conducted based on &ldquo;data classification and hierarchical
protection system&rdquo; for the purpose of data protection and prohibits entities in China from transferring data stored in China to
foreign law enforcement agencies or judicial authorities without prior approval by the Chinese government. As the Data Security Law has
not yet come into effect, we may need to make adjustments to our data processing practices to comply with this law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, China&rsquo;s
Cyber Security Law, requires companies to take certain organizational, technical and administrative measures and other necessary measures
to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that China adopt
a multi-level protection scheme (MLPS), under which network operators are required to perform obligations of security protection to ensure
that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed, stolen or
tampered. Under the MLPS, entities operating information systems must have a thorough assessment of the risks and the conditions of their
information and network systems to determine the level to which the entity&rsquo;s information and network systems belong-from the lowest
Level 1 to the highest Level 5 pursuant to the Measures for the Graded Protection and the Guidelines for Grading of Classified Protection
of Cyber Security. The grading result will determine the set of security protection obligations that entities must comply with. Entities
classified as Level 2 or above should report the grade to the relevant government authority for examination and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Recently, the Cyberspace Administration
of China has taken action against several Chinese internet companies in connection with their initial public offerings on U.S. securities
exchanges, for alleged national security risks and improper collection and use of the personal information of Chinese data subjects. According
to the official announcement, the action was initiated based on the National Security Law, the Cyber Security Law and the Measures on
Cybersecurity Review, which are aimed at &ldquo;preventing national data security risks, maintaining national security and safeguarding
public interests.&rdquo; On July 10, 2021, the Cyberspace Administration of China published a revised draft of the Measures on Cybersecurity
Review, expanding the cybersecurity review to data processing operators in possession of personal information of over 1 million users
if the operators intend to list their securities in a foreign country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is unclear at the present
time how widespread the cybersecurity review requirement and the enforcement action will be and what effect they will have on the life
sciences sector generally and the Company in particular. China&rsquo;s regulators may impose penalties for non-compliance ranging from
fines or suspension of operations, and this could lead to us delisting from the U.S. stock market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Also, on August 20, 2021,
the National People&rsquo;s Congress passed the Personal Information Protection Law, started to be implemented on November 1, 2021. The
law creates a comprehensive set of data privacy and protection requirements that apply to the processing of personal information and expands
data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in
China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing
products and services to, or analyzing and evaluating the behavior of, persons in China. The law also proposes that critical information
infrastructure operators and personal information processing entities who process personal information meeting a volume threshold to-be-set
by Chinese cyberspace regulators are also required to store in China personal information generated or collected in China, and to pass
a security assessment administered by Chinese cyberspace regulators for any export of such personal information. Lastly, the draft contains
proposals for significant fines for serious violations of up to RMB 50 million or 5% of annual revenues from the prior year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interpretation, application
and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation,
amendments to existing legislation and changes in enforcement. Compliance with the Cyber Security Law and the Data Security Law could
significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even prevent
us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future. Despite
our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security,
it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed on us by the Cyber Security
Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulations or
any other obligations relating to privacy, data protection or information security, or any compromise of security that results in unauthorized
access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing
types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting
with us or result in investigations, fines, suspension or other penalties by Chinese government authorities and private claims or litigation,
any of which could materially adversely affect our business, financial condition and results of operations. Even if our practices are
not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and brand and adversely
affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law and
the recent Chinese government actions could materially adversely affect our ability, on favorable terms, to raise capital, including engaging
in follow-on offerings of our securities in the U.S. market or the Stock Exchange of Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our auditor is headquartered in the United
States, and is subject to inspection by the PCAOB on a regular basis. To the extent that our independent registered public accounting
firm&rsquo;s audit documentation related to their audit reports for our company become located in China, the PCAOB may not be able inspect
such audit documentation and, as such, you may be deprived of the benefits of such inspection and our common stock could be delisted from
the stock exchange pursuant to the Holding Foreign Companies Accountable Act.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent registered
public accounting firm issued an audit opinion on the financial statements incorporated by reference in this prospectus supplement filed
with the SEC and will issue audit reports related to our company in the future. As auditors of companies that are traded publicly in the
United States and a firm registered with the PCAOB, our auditor is required by the laws of the United States to undergo regular inspections
by the PCAOB. However, to the extent that our auditor&rsquo;s work papers become located in China, such work papers will not be subject
to inspection by the PCAOB because the PCAOB is currently unable to conduct inspections without the approval of the Chinese authorities.
Inspections of certain other firms that the PCAOB has conducted outside of China have identified deficiencies in those firms&rsquo; audit
procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. We
are required by the Holding Foreign Companies Accountable Act to have an auditor that is subject to the inspection by the PCAOB. While
our present auditor is located in the United States and the PCAOB is able to conduct inspections on such auditor, to the extent this status
changes in the future and our auditor&rsquo;s audit documentation related to their audit reports for our company becomes outside of the
inspection by the PCAOB, our common stock could be delisted from the stock exchange pursuant to the Holding Foreign Companies Accountable
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will not receive any of the proceeds from the issuance of the shares to the Noteholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will bear all other costs, fees and expenses incurred in connection with the registration of the securities covered by this prospectus
supplement. These may include, without limitation, SEC filing fees, Nasdaq listing fees, fees and expenses of our counsel and accountants,
blue sky fees and expenses, and fees to be paid to the depositary bank pursuant to the agreements with respective Noteholder if the Noteholder
elect to deposit the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_006"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are registering the shares of our common stock issuable upon conversion of the Note from time to time after the date of this prospectus
supplement. We will not receive any of the proceeds from the issuance of the shares to the Noteholder. We will bear all fees and expenses
incident to our obligation to register the shares. The registration of the issuance of the shares hereunder does not necessarily mean
that the Noteholder will convert the Note to common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will pay all costs, fees and expenses incurred in connection with the registration of the shares pursuant to registration rights agreements
with the Noteholder, including, without limitation, all SEC filing fees, Nasdaq listing fees, fees and expenses of our counsel and accountants,
blue sky fees and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus supplement and the accompanying prospectus cover the issuance of shares of our common stock upon the conversion of the Note
by Noteholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_007"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Selected
legal matters with respect to the validity of the securities offered by this prospectus supplement will be passed upon for us by Flangas
Law Group, Las Vegas, NV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_008"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The
consolidated balance sheets of China Pharma Holdings, Inc. and it subsidiaries as of December 31, 2020 and 2019, the related consolidated
statements of operations and comprehensive income (loss), stockholders&rsquo; equity, and cash flows for each of the two years in the
period ended December 31, 2020, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;), incorporated
in this prospectus by reference to our Annual Report on Form 10-K for the year ended December 31, 2020, have been so incorporated in reliance
upon the report of BF Borgers CPA, P.C., an independent registered public accounting firm, given on the authority of such firm as experts
in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_009"></A>WHERE YOU CAN FIND
MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the securities we are offering under
this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth
in the registration statement and the exhibits to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For
further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration
statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus supplement
as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you
to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified
in all respects by this reference. We file annual, quarterly and current reports, proxy statements and other information with the SEC.
Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website at http:/www.sec.gov. Because our common stock
is listed on the NYSE American, you may also inspect reports, proxy statements and other information at the offices of the NYSE American
Information found on our website is not part of this prospectus supplement or any other report we file with or furnish to the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="S_010"></A>IMPORTANT INFORMATION
INCORPORATED BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents filed
by us with the Securities and Exchange Commission are incorporated by reference in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021017981/f10k2020_chinapharma.htm">Form 10-K</A> for the fiscal year ended December 31, 2020, filed on March 26, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021058670/f10q0921_chinapharma.htm">Form 10-Q</A> for the fiscal quarter ended September 30, 2021, filed on November 12, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021042474/f10q0621_chinapharmahold.htm">Form 10-Q</A> for the fiscal quarter ended June 30, 2021, filed on August 13, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021026413/f10q0321_chinapharmahold.htm">Form 10-Q</A> for the fiscal quarter ended March 31, 2021, filed on May 14, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Current Reports on Form 8-K, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021048212/ea147480-8k_chinapharma.htm">September 15, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021061610/ea151262-8k_chinapharma.htm">November 23, 2021</A>, respectively;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390021059533/ea150670-def14a_chinapharma.htm">Schedule 14A</A>, filed with the SEC on November 15, 2021;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The description of our common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054909000661/cph812b092809.htm">Form 8-A12B</A> filed pursuant to Section 12 of the Exchange Act on September 28, 2009, including any amendment or report filed with the Commission for the purpose of updating this description ; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All of our filings made with the Securities and Exchange Commission pursuant to the Exchange Act after the date of the initial registration statement of which this prospectus forms a part and prior to the effectiveness of the registration statement of which this prospectus forms a part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents subsequently
filed with the Securities and Exchange Commission by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the
date of this prospectus and prior to the filing of a post-effective amendment which indicates that all securities offered herein have
been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be
part of this prospectus from the respective dates of filing of such documents. Any statement contained herein or in a document incorporated
or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes hereof or of the related prospectus
supplement to the extent that a statement contained herein or in any other subsequently filed document which is also incorporated or deemed
to be incorporated herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except
as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We will provide to each
person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that has been incorporated
by reference in the prospectus but not delivered with the prospectus. You may request a copy of these filings, excluding the exhibits
to such filings which we have not specifically incorporated by reference in such filings, at no cost, by writing us at China Pharma Holdings,
Inc., 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China, or calling us at 86-10-898-66811730.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Statements
contained in this prospectus supplement as to the contents of any contract or other documents are not necessarily complete, and in each
instance you are referred to the copy of the contract or other document filed as an exhibit to the registration statement or incorporated
herein, each such statement being qualified in all respects by such reference and the exhibits and schedules thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Subject to Completion, Dated January 8, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$50,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Debt Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may offer and sell, from time to time in one or more offerings,
any combination of common stock, preferred stock, debt securities (which may be convertible into or exchangeable for common stock),
warrants, rights or units that include any of these securities having an aggregate initial offering price not exceeding $50,000,000.
When we decide to sell a particular class or series of securities, we will provide specific terms of the offered securities in
a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide specific terms of the offerings
of our securities in supplements to this prospectus. The prospectus supplement may also add, update or change information contained
in or incorporated by reference into this prospectus. You should read this prospectus and any prospectus supplement, as well as
the documents incorporated by reference or deemed to be incorporated by reference into this prospectus, carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus may not be used to offer
or sell our securities unless accompanied by a prospectus supplement relating to the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on the NYSE American (formerly known
as AMEX) under the symbol &ldquo;CPHI&rdquo;. The closing price for our common stock on NYSE American on January 7, 2021 was $0.55
per share. Each prospectus supplement will contain information, where applicable, as to any listing on the NYSE American or any
other securities exchange of the securities covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These securities may be sold directly by
us, through dealers or agents designated from time to time, to or through underwriters or through a combination of these methods.
See &ldquo;Plan of Distribution&rdquo; in this prospectus. We may also describe the plan of distribution for any particular offering
of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved in the sale of any securities
in respect of which this prospectus is being delivered, we will disclose their names and the nature of our arrangements with them
in a prospectus supplement. The net proceeds we expect to receive from any such sale will also be included in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities
involves risk. You should carefully consider the risk factors beginning on page 5 of this prospectus before investing in our
securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THE SECURITIES AND EXCHANGE
COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES, OR PASSED UPON THE ADEQUACY OR
ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">The date of
this prospectus is</FONT> __________<FONT STYLE="font-size: 10pt">, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 95%"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle; width: 5%">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">ABOUT OUR COMPANY</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">2</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">5</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">THE SECURITIES WE MAY OFFER</FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: middle">6</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF COMMON STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">7</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">8</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">9</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">DESCRIPTION OF RIGHTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">11</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">12</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: middle; text-align: center">15</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should rely only on the information
contained or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide
you with information different from that contained or incorporated by reference into this prospectus. If any person does provide
you with information that differs from what is contained or incorporated by reference in this prospectus, you should not rely on
it. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this
prospectus. You should assume that the information contained in this prospectus or any prospectus supplement is accurate only as
of the date on the front of the document and that any information contained in any document we have incorporated by reference is
accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or
any prospectus supplement or any sale of a security. These documents are not an offer to sell or a solicitation of an offer to
buy these securities in any circumstances under which the offer or solicitation is unlawful.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 6pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus is part
of a Registration Statement on Form S-3 that we filed with the Securities and Exchange Commission utilizing a &ldquo;shelf&rdquo;
registration process. Under this shelf process, we may sell common stock, preferred stock, debt securities (which may be convertible
into or exchangeable for common stock), warrants, rights or units from time to time in one or more offerings at indeterminate prices,
up to an aggregate maximum offering price for all such securities of $50,000,000. This prospectus provides you with a general description
of the securities we may offer. Each time we sell any securities under this prospectus, we will provide a prospectus supplement
that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change
information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional
information described below under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus and
any accompanying prospectus supplement or other offering materials do not contain all of the information included in the registration
statement as permitted by the rules and regulations of the SEC. For further information, we refer you to the registration statement
on Form S-3, including its exhibits. We are subject to the informational requirements of the Securities Exchange Act of 1934, as
amended (the &ldquo;Exchange Act&rdquo;), and, therefore, file reports and other information with the SEC. Statements contained
in this prospectus and any accompanying prospectus supplement, or other offering materials about the provisions or contents of
any agreement or other document are only summaries. If SEC rules require that any agreement or document be filed as an exhibit
to the registration statement, you should refer to that agreement or document for its complete contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should not assume
that the information in this prospectus, any prospectus supplement or any other offering materials is accurate as of any date other
than the date on the front of each document. Our business, financial condition, results of operations and prospects may have changed
since then.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated
in this prospectus or the context otherwise requires, references to &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;China Pharma&rdquo;,
&ldquo;the Company&rdquo; or &ldquo;our Company&rdquo; refer to China Pharma Holdings, Inc. and its wholly owned subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</DIV>


<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 6pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>ABOUT OUR COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Organization and Nature of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China Pharma Holdings,
Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100%
of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&rsquo;s Republic
of China (the &ldquo;PRC&rdquo;). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Onny acquired 100%
of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson&rsquo;s three former shareholders.
The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate
of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business
license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate organizational
chart is set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has acquired
and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview &amp; Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are principally
engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of
high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of our operations are conducted in
the PRC, where our manufacturing facilities are located. We manufacture pharmaceutical products in the form of dry powder injectables,
liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of our pharmaceutical products are sold on
a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products
Administration (the &ldquo;NMPA&rdquo;, formerly China Food and Drug Administration, CFDA) based upon demonstrated safety and efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">China&rsquo;s consistency
evaluation of generic drugs had continued to proceed in 2019. The supporting policies from central and provincial governments have
been constantly issued. We have always taken the tasks of facilitating the consistency evaluation as our top priority, and worked
on them actively. However, due to the continuous dynamic changes of the detailed policies, future market, expected investment,
and return of investment (&ldquo;ROI&rdquo;) for each drug&rsquo;s consistency evaluation, the whole industry, including us, has
been making slow progresses in terms of the consistency evaluation.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 6pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have to take a more
cautious and flexible attitude towards the initiating and progressing any project for an existing product&rsquo;s consistency evaluation
and to cope with the changing macro environment of drug sales in China. On one hand, since initiated in 2018, two rounds of &ldquo;4
+ 7&rdquo; (refers to 11 selected pilot cities, including 4 municipalities and 7 other cities) Group Purchasing Organization (&ldquo;GPO&rdquo;)
activities had been carried out by the end of 2019, which significantly reduced the price of the drugs that won the bids. On the
other hand, the consistency evaluation has been adopted as one of the qualification standards for participating in the GPO activities.
As a result, we need balance at least the two factors above before making decisions for any project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we continue
to explore in the field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed according to the development
of the times, social needs and changes in disease spectrum. It focuses on people&rsquo;s daily life, aging and disease, pays attention
to all kinds of risk factors and misunderstandings affecting health, and calls for self-health management, and advocates the comprehensive
care of the entire process of life. It covers all kinds of health-related information, products and services, as well as actions
taken by various organizations to meet the health needs. We launched Noni enzyme, a natural, healthy and nutrition-rich food supplement
at the end of 2018, and wash-free sanitizer and mask in early 2020 to address the market needs caused by COVID-19 in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will continue to
optimize our product structure and actively respond to the current health needs of human beings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Trends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As the medical reform
deepens, the GPO program has been expanded from pilot cities to the whole country, which pressed hospitals to control drug prices
to reduce overall costs. The pressure of price reduction has been further transmitted to pharmaceutical manufacturers. We believe
that the price control is still one of the key themes in the pharmaceutical industry in the future; and pharmaceutical manufacturing
companies&rsquo; revenues are under obvious pressure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Novel coronavirus pneumonia
(COVID-19) refers to the pneumonia caused by the 2019 novel coronavirus infection. World Health Organization (WHO) convened the
COVID-19 Emergency Committee for the fifth time to assess the global outbreak situation and provide recommendations for response
on October 29, 2020. WHO then announced that the outbreak of COVID-19 continues to constitute a &ldquo;public health emergency
of international concern&rdquo; on October 30, 2020. Due to the impact of COVID-19 pandemic, there has been a phenomenon that people
are afraid of going to the hospital. The decline in the number of hospital outpatients has created a negative pressure on sales
for pharmaceutical companies, including ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a generic drug company
we are presented with a huge domestic market. We believe that through further upgrades and consistency evaluations, we will be
able to meet the European and American production standards, which enables us to export our products to overseas markets. In the
future, cost management and control ability will gradually become an important factor in determining the competitiveness of generic
pharmaceutical enterprises. Although price control leads to a decline in the profitability, the GPO&rsquo;s winning enterprise
has a good chance of achieving price-for-volume in order to increase its market share and support its continuous innovation transformation.
In addition, consumption upgrading in China drives the increase of optional consumption. With the improvement of residents&rsquo;
quality of life, the healthcare demand is also changing. We believe that there are a large number of unmet demands in comprehensive
healthcare and Internet healthcare sectors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, demand
for pharmaceutical products is still experiencing steady growth in China. We believe the ongoing generic drug consistency evaluations
and reform of China&rsquo;s drug production registration and review policies will have major effects on the future development
of our industry and may change its business patterns. We will continue to actively adapt to the national policy guidance and further
evaluate market conditions for our existing products, and competition in the market in order to optimize our development strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Offices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
offices are located at 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China. Our telephone number at that address is
+86-898-66811730.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 6pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The statements contained
in this Form S-3 that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities
Act, and Section 21E of the Exchange Act. These include statements about the Company&rsquo;s expectations, beliefs, intentions
or strategies for the future, which are indicated by words or phrases such as &ldquo;anticipate&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;,
&ldquo;plan&rdquo;, &ldquo;will&rdquo;, &ldquo;the Company believes&rdquo;, &ldquo;management believes&rdquo; and similar words
or phrases. The forward-looking statements are based on the Company&rsquo;s current expectations and are subject to certain risks,
uncertainties and assumptions. The Company&rsquo;s actual results could differ materially from results anticipated in these forward-looking
statements. All forward-looking statements included in this document are based on information available to the Company on the date
hereof, and the Company assumes no obligation to update any such forward-looking statements.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investing in our common
stock involves risk. You should carefully consider the specific risks discussed or incorporated by reference into the applicable
prospectus supplement, together with all the other information contained in the prospectus supplement or incorporated by reference
into this prospectus and the applicable prospectus supplement. You should also consider the risks, uncertainties and assumptions
discussed under the caption &ldquo;Risk Factors&rdquo; included in our Annual Report on Form 10-K for the year ended December 31,
2019, and in subsequent filings, which are incorporated by reference into this prospectus. These risk factors may be amended, supplemented
or superseded from time to time by other reports we file with the SEC in the future or by a prospectus supplement relating to a
particular offering of common stock. These risks and uncertainties are not the only risks and uncertainties we face. Additional
risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any
of the risks or uncertainties described in our SEC filings or any prospectus supplement or any additional risks and uncertainties
actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that
case, the trading price of our securities could decline and you might lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Securities and the Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Future sales
or other dilution of our equity could depress the market price of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our common
stock, preferred stock, warrants, rights or convertible debt securities, or any combination of the foregoing, in the public market,
or the perception that such sales could occur, could negatively impact the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the issuance
of additional shares of our common stock, securities convertible into or exercisable for our common stock, other equity-linked
securities, including preferred stock, warrants or rights or any combination of these securities pursuant to this prospectus will
dilute the ownership interest of our common shareholders and could depress the market price of our common stock and impair our
ability to raise capital through the sale of additional equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need to seek
additional capital. If this additional financing is obtained through the issuance of equity securities, debt securities convertible
into equity or options, warrants or rights to acquire equity securities, our existing shareholders could experience significant
dilution upon the issuance, conversion or exercise of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Our management
will have broad discretion over the use of the proceeds we receive from the sale our securities pursuant to this prospectus and
might not apply the proceeds in ways that increase the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will
have broad discretion to use the net proceeds from any offerings under this prospectus, and you will be relying on the judgment
of our management regarding the application of these proceeds. Except as described in any prospectus supplement or in any related
free writing prospectus that we may authorize to be provided to you, the net proceeds received by us from our sale of the securities
described in this prospectus will be added to our general funds and will be used for general corporate purposes. Our management
might not apply the net proceeds from offerings of our securities in ways that increase the value of your investment and might
not be able to yield a significant return, if any, on any investment of such net proceeds. You may not have the opportunity to
influence our decisions on how to use such proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as otherwise
provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities covered by
this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development
expenditures, acquisitions of new technologies or businesses and investments. Additional information on the use of net proceeds
from an offering of securities covered by this prospectus may be set forth in the prospectus supplement relating to the specific
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>THE SECURITIES WE MAY OFFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The descriptions of
the securities contained in this prospectus, together with any applicable prospectus supplement, summarize all the material terms
and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating
to a particular offering the specific terms of the securities offered by that prospectus supplement. If we indicate in the applicable
prospectus supplement, the terms of the securities may differ from the terms we have summarized below. We will also include in
the prospectus supplement information, where applicable, about material United States federal income tax considerations relating
to the securities, and the securities exchange, if any, on which the securities will be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell from time to
time, in one or more offerings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">shares of our common stock,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">shares of our preferred stock,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">debt securities (which may be convertible into or exchangeable for common stock),</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">warrants to purchase our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">rights to purchase our common stock and/or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">units consisting of the forgoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus may not
be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of our capital stock together with the additional information we include in any applicable prospectus supplement, summarizes the
material terms and provisions of the capital stock that we may offer under this prospectus but is not complete. For the complete
terms of our capital stock, please refer to our articles of incorporation and our bylaws, as amended from time to time. While the
terms we have summarized below will apply generally to any future capital stock that we may offer, we will describe the specific
terms of any series of these securities in more detail in the applicable prospectus supplement. If we so indicate in a prospectus
supplement, the terms of any capital stock we offer under that prospectus supplement may differ from the terms we describe below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock consists of ninety-five million
(95,000,000) shares of common stock, $0.001 par value per share and five million (5,000,000) shares of preferred stock, $0.001
par value per share. The authorized and unissued shares of capital stock are available for issuance without further action by our
shareholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be
listed. Unless approval of our shareholders is so required, our board of directors will not seek shareholder approval for the issuance
and sale of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 8, 2021, there were 45,579,557 shares of our common
stock outstanding. The holders of our common stock are entitled to such dividends as our board of directors may declare from legally
available funds. The holders of our common stock are entitled to one vote per share on any matter to be voted upon by shareholders.
Our articles of incorporation or our bylaws, as amended from time to time, do not provide for cumulative voting. No holder of our
common stock has any preemptive right to subscribe for any shares of capital stock issued in the future under the Nevada Revised
Statutes, our articles of incorporation or our bylaws, as amended from time to time. Our common stock has no preemptive or conversion
rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All shares of common
stock offered hereby will, when issued, be fully paid and non-assessable, including shares of common stock issued upon exercise
of common stock warrants or common stock purchase rights, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is quoted on the NYSE American
under the symbol &ldquo;CPHI&rdquo;. The transfer agent and registrar for our common stock is Equiniti Trust Company (f/k/a Corporate
Stock Transfer), 3200 E Cherry Creek South Dr Ste 430, Denver, CO 80209.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><A NAME="a_008"></A>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 8, 2021,
no shares of preferred stock had been issued or were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has the authority to issue up to 5,000,000
shares of preferred stock in one or more series and to determine the rights and preferences of the shares of any such series without
stockholder approval. Our board of directors has the authority to fix the designation and powers, rights and preferences and the
qualifications, limitations or restrictions with respect to each class or series of such class without further vote or action by
the stockholders, unless action is required by applicable law or the rules of any stock exchange on which our securities may be
listed. The ability of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying,
deferring or preventing a change of control of us or the removal of existing management. Further, our board of directors may authorize
the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of
the holders of our common stock. Additionally, the issuance of preferred stock may have the effect of decreasing the market price
of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will file as an
exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we
file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are
offering before the issuance of that series of preferred stock. This description will include, but not be limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the title and stated value;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the number of shares we are offering;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the liquidation preference per share;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the purchase price;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the dividend rate, period and payment date and method of calculation for dividends;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which
dividends will accumulate;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the provisions for a sinking fund, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability
to exercise those redemption and repurchase rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">whether the preferred stock will be convertible into our common stock, and, if applicable, the
conversion price, or how it will be calculated, and the conversion period;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the
exchange price, or how it will be calculated, and the exchange period;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">voting rights, if any, of the preferred stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">preemptive rights, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">restrictions on transfer, sale or other assignment, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">a discussion of any material United States federal income tax considerations applicable to the
preferred stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the relative ranking and preferences of the preferred stock as to dividend rights and rights if
we liquidate, dissolve or wind up our affairs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any limitations on the issuance of any class or series of preferred stock ranking senior to or
on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred
stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue debt securities,
in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. When we offer to sell
debt securities, we will describe the specific terms of any debt securities offered from time to time in a supplement to this prospectus,
which may supplement or change the terms outlined below. Senior debt securities will be issued under one or more senior indentures,
dated as of a date prior to such issuance, between us and a trustee to be named in a prospectus supplement, as amended or supplemented
from time to time. Any subordinated debt securities will be issued under one or more subordinated indentures, dated as of a date
prior to such issuance, between us and a trustee to be named in a prospectus supplement, as amended or supplemented from time to
time. The indentures will be subject to and governed by the Trust Indenture Act of 1939, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before we issue any
debt securities, the form of indentures will be filed with the SEC and incorporated by reference as an exhibit to the registration
statement of which this prospectus is a part or as an exhibit to a current report on Form 8-K. For the complete terms of the debt
securities, you should refer to the applicable prospectus supplement and the form of indentures for those particular debt securities.
We encourage you to read the applicable prospectus supplement and the form of indenture for those particular debt securities before
you purchase any of our debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in
the applicable prospectus supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the title;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">whether or not such debt securities are guaranteed;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the principal amount being offered, and if a series, the total amount authorized and the total
amount outstanding;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any limit on the amount that may be issued;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">whether or not we will issue the series of debt securities in global form, the terms and who the
depositary will be;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the maturity date;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the annual interest rate, which may be fixed or variable, or the method for determining the rate
and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment
dates or the method for determining such dates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the terms of the subordination of any series of subordinated debt;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the place where payments will be payable;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">restrictions on transfer, sale or other assignment, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the date, if any, after which, and the price at which, we may, at our option, redeem the series
of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt
securities and the currency or currency unit in which the debt securities are payable;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any restrictions our ability and/or the ability of our subsidiaries to:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">incur additional indebtedness;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">issue additional securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">create liens;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">pay dividends and make distributions in respect of our capital stock and
the capital stock of our subsidiaries;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">redeem capital stock;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">place restrictions on our subsidiaries&rsquo; ability to pay dividends, make
distributions or transfer assets;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">make investments or other restricted payments;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">sell or otherwise dispose of assets;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">enter into sale-leaseback transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">engage in transactions with stockholders and affiliates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">issue or sell stock of our subsidiaries; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0.5in">effect a consolidation or merger;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based,
asset-based or other financial ratios;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">a discussion of any material United States federal income tax considerations applicable to the
debt securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">information describing any book-entry features;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">provisions for a sinking fund purchase or other analogous fund, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the denominations in which we will issue the series of debt securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the currency of payment of debt securities if other than U.S. dollars and the manner of determining
the equivalent amount in U.S. dollars; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities,
including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be
required by us or advisable under applicable laws or regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description,
together with the additional information we may include in any applicable prospectus supplement, summarizes the material terms
and provisions of the warrants that we may offer under this prospectus and any related warrant agreement and warrant certificate.
While the terms summarized below will apply generally to any warrants that we may offer, we will describe the specific terms of
any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the
terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements
will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration
statement which includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue warrants
for the purchase of common stock in one or more series. We may issue warrants independently or together with common stock, and
the warrants may be attached to or separate from common stock. We may issue the warrants under warrant agreements to be entered
into between us and a bank or trust company, as warrant agent, all as described in the prospectus supplement. If we issue the warrants
under warrant agreements, the warrant agent will act solely as our agent in connection with the warrants and will not assume any
obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the terms summarized
below will apply generally to any warrants that we may offer, we will describe the particular terms of any series of warrants in
more detail in the applicable prospectus supplement. The terms of any warrants offered under a prospectus supplement may differ
from the terms described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the offering price and aggregate number of warrants offered;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">if applicable, the designation and terms of the securities with which the warrants are issued and
the number of warrants issued with each such security;&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">if applicable, the date on and after which the warrants and the related securities will be separately
transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">in the case of warrants to purchase common stock, the number or amount of shares of common stock
purchasable upon the exercise of one warrant and the price at which and currency in which these shares may be purchased upon such
exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the manner of exercise of the warrants, including any cashless exercise rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the warrant agreement under which the warrants will be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the effect of any merger, consolidation, sale or other disposition of our business on the warrant
agreement and the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">anti-dilution provisions of the warrants, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the terms of any rights to redeem or call the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any provisions for changes to or adjustments in the exercise price or number of securities issuable
upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the dates on which the right to exercise the warrants will commence and expire or, if the warrants
are not continuously exercisable during that period, the specific date or dates on which the warrants will be exercisable;&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the manner in which the warrant agreement and warrants may be modified;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the identities of the warrant agent and any calculation or other agent for the warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">federal income tax consequences of holding or exercising the warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the terms of the securities issuable upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any securities exchange or quotation system on which the warrants or any securities deliverable
upon exercise of the warrants may be listed or quoted; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before exercising their
warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">in the case of warrants to purchase common stock the right to receive dividends, if any, or, payments
upon our liquidation, dissolution or winding up or to exercise voting rights, if any.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each warrant will entitle
the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. Holders of the warrants may exercise the warrants at any time up to the close of business
on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration
date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the warrants
may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified
information, and paying the required exercise price by the methods provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate, and in the applicable prospectus supplement, the information that the holder
of the warrant will be required to deliver to the warrant agent or any other office indicated in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of the
required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant
agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable
upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue
a new warrant certificate for the remaining amount of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights By Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any warrant agent will
act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or
trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants.
A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant,
including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder
of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal
action the holder&rsquo;s right to exercise, and receive the securities purchasable upon exercise of, its warrants in accordance
with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrant Agreement Will Not Be Qualified Under Trust Indenture
Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No warrant agreement
will be qualified as an indenture, and no warrant agent will be required to qualify as a trustee, under the Trust Indenture Act.
Therefore, holders of warrants issued under a warrant agreement will not have the protection of the Trust Indenture Act with respect
to their warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we provide otherwise
in the applicable prospectus supplement, each warrant agreement and any warrants issued under the warrant agreements will be governed
by New York law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>DESCRIPTION OF RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue rights
to purchase our common stock or preferred stock, in one or more series. Rights may be issued independently or together with any
other offered security and may or may not be transferable by the person purchasing or receiving the subscription rights. In connection
with any rights offering to our stockholders, we may enter into a standby underwriting arrangement with one or more underwriters
pursuant to which such underwriters will purchase any offered securities remaining unsubscribed after such rights offering. In
connection with a rights offering to our stockholders, we will distribute certificates evidencing the rights and a prospectus supplement
to our stockholders on the record date that we set for receiving rights in such rights offering. The applicable prospectus supplement
or free writing prospectus will describe the following terms of rights in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the title of such rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the securities for which such rights are exercisable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the exercise price for such rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date of determining the security holders entitled to the rights distribution;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of such rights issued to each security holder;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the extent to which such rights are transferable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, a discussion of the material United States federal income tax considerations applicable to the issuance or exercise of such rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the date on which the right to exercise such rights shall commence, and the date on which such rights shall expire (subject to any extension);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the conditions to completion of the rights offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the material terms of any standby underwriting or other purchase arrangement that we may enter into in connection with the rights offering; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">any other terms of such rights, including terms, procedures and limitations relating to the exchange and exercise of such rights.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each right will entitle
the holder thereof the right to purchase for cash such amount of shares of common stock or preferred stock, or any combination
thereof, at such exercise price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement
relating to the rights offered thereby. Rights may be exercised at any time up to the close of business on the expiration date
for such rights set forth in the prospectus supplement. After the close of business on the expiration date, all unexercised rights
will become void. Rights may be exercised as set forth in the prospectus supplement relating to the rights offered thereby. Upon
receipt of payment and the proper completion and due execution of the rights certificate at the office of the rights agent, if
any, or any other office indicated in the prospectus supplement, we will forward, as soon as practicable, the shares of common
stock and/or preferred stock purchasable upon such exercise. We may determine to offer any unsubscribed offered securities directly
to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including
pursuant to standby underwriting arrangements, as set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units
comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so that
the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit.
The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred
separately, at any time or at any time before a specified date or upon the occurrence of a specified event or occurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplement will describe:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the designation and terms of the units and of the securities comprising the units, including whether
and under what circumstances those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any unit agreement under which the units will be issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the
securities comprising the units; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">whether the units will be issued in fully registered or global form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
being offered pursuant to this prospectus to or through underwriters, through dealers, through agents, or directly to one or more
purchasers or through a combination of these methods. The applicable prospectus supplement will describe the terms of the offering
of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the name or names of any underwriters, if any, and if required, any dealers or agents;&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">the purchase price of the securities and the proceeds we will receive from the sale;&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any underwriting discounts and other items constituting underwriters&rsquo; compensation;&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any discounts or concessions allowed or reallowed or paid to dealers; and&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">any securities exchange or market on which the securities may be listed or traded.&#9;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may distribute the securities from time
to time in one or more transactions at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales Through Underwriters or Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only underwriters named
in the prospectus supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are
used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter
and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters
and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates
represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting
syndicate is used, the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are
used in the sale, the offered securities will be acquired by the underwriters for their own accounts and may be resold from time
to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be
changed from time to time. Unless otherwise set forth in the prospectus supplement, the obligations of the underwriters to purchase
the offered securities will be subject to conditions precedent and the underwriters will be obligated to purchase all of the offered
securities, if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may grant to the
underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional
underwriting commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment
option will be set forth in the prospectus supplement for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we use a dealer
in the sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities
to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the
dealer at the time of resale. The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Direct Sales and Sales Through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities
and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states
otherwise, any agent will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with
respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may authorize agents
or underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth
in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the
future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts
in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the sale of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the securities
for whom they act as agents, in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through
dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters
or commissions from the purchasers for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution
of the securities, and any institutional investors or others that purchase securities directly for the purpose of resale or distribution,
may be deemed to be underwriters, and any discounts or commissions received by them from us and any profit on the resale of the
common stock by them may be deemed to be underwriting discounts and commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may provide agents,
underwriters and other purchasers with indemnification against particular civil liabilities, including liabilities under the Securities
Act, or contribution with respect to payments that the agents, underwriters or other purchasers may make with respect to such liabilities.
Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To facilitate the public
offering of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain,
or otherwise affect the market price of the securities. This may include over-allotments or short sales of the securities, which
involves the sale by persons participating in the offering of more securities than have been sold to them by us. In those circumstances,
such persons would cover such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment
option granted to those persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for
or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or
dealers participating in any such offering may be reclaimed if securities sold by them are repurchased in connection with stabilization
transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above
that which might otherwise prevail in the open market. Such transactions, if commenced, may be discontinued at any time. We make
no representation or prediction as to the direction or magnitude of any effect that the transactions described above, if implemented,
may have on the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, any common stock sold pursuant to a prospectus supplement will be eligible for listing
on the NYSE American, subject to official notice of issuance. Any underwriters to whom securities are sold by us for public offering
and sale may make a market in the securities, but such underwriters will not be obligated to do so and may discontinue any market
making at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_014"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the
issuance of the securities offered hereby will be passed upon for us by FLANGAS LAW GROUP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_015"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated balance
sheets of China Pharma Holdings, Inc. and it subsidiaries as of December 31, 2019 and 2018, the related consolidated statements
of operations and comprehensive income (loss), stockholders&rsquo; equity, and cash flows for each of the two years in the period
ended December 31, 2019, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;), incorporated
in this prospectus by reference to our Annual Report on Form 10-K for the year ended December 31, 2019, have been so incorporated
in reliance upon the report of BF Borgers CPA, P.C., an independent registered public accounting firm, given on the authority of
such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_016"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a public company
and file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any
document we file at the SEC&rsquo;s public reference room at 100 F Street, NE, Washington, D.C. 20549. You can request copies
of these documents by writing to the SEC and paying a fee for the copying cost. Please call the SEC at 1-800-SEC-0330 for more
information about the operation of the public reference room. Our SEC filings are also available, at no charge, to the public
at the SEC&rsquo;s web site at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents
filed by us with the Securities and Exchange Commission are incorporated by reference in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020008020/f10k2019_chinapharmahold.htm">Form 10-K</A> for the fiscal year ended December 31, 2019, filed on March 30, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020036919/f10q0920_chinapharmahold.htm">Form 10-Q</A> for the fiscal quarter ended September 30, 2020, filed on November
13, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020021867/f10q0620_chinapharmaholdings.htm">Form 10-Q</A> for the fiscal quarter ended June 30, 2020, filed on August 13, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020012258/f10q0320_chinapharmaholdings.htm">Form 10-Q</A> for the fiscal quarter ended March 31, 2020, filed on May 14, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020045181/ea132375-8k_chinapharma.htm">Form 8-K</A>, filed on December 29, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000121390020037345/ea129945-def14a_chinapharma.htm">Schedule 14A</A>, filed with the SEC on November 16, 2020;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">The description of our common stock contained in the Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1106644/000101054909000661/cph812b092809.htm">Form 8-A12B</A> filed
pursuant to Section 12 of the Exchange Act on September 28, 2009, including any amendment or report filed with the Commission for
the purpose of updating this description ; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px">&#9679;</TD><TD STYLE="text-align: justify">All of our filings made with the Securities and Exchange Commission pursuant to the Exchange Act
after the date of the initial registration statement of which this prospectus forms a part and prior to the effectiveness of the
registration statement of which this prospectus forms a part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All documents subsequently
filed with the Securities and Exchange Commission by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after
the date of this prospectus and prior to the filing of a post-effective amendment which indicates that all securities offered herein
have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein
and to be part of this prospectus from the respective dates of filing of such documents. Any statement contained herein or in a
document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
hereof or of the related prospectus supplement to the extent that a statement contained herein or in any other subsequently filed
document which is also incorporated or deemed to be incorporated herein modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We will provide
to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that
has been incorporated by reference in the prospectus but not delivered with the prospectus. You may request a copy of these filings,
excluding the exhibits to such filings which we have not specifically incorporated by reference in such filings, at no cost, by
writing us at China Pharma Holdings, Inc., 2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China, or calling us at 86-10-898-66811730.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is
part of a registration statement we filed with the Securities and Exchange Commission. You should only rely on the information
or representations contained in this prospectus and any accompanying prospectus supplement. We have not authorized anyone to provide
information other than that provided in this prospectus and any accompanying prospectus supplement. We are not making an offer
of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus
or any accompanying prospectus supplement is accurate as of any date other than the date on the front of the document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$50,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Preferred Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Debt Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Units</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 35%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is _____________,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 2P# 2(  A$! Q$!_\0
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MS#S_ /)O\C^C[_B)B_;]_P">?P9_\-WI_P#\L*/^(F+]OW_GG\&?_#=Z?_\
M+"OYUH]+L)[JYF3[9]B^TW&C11V^J:7/!_:'^B?9+K_N(_Z9QZFL2.S?=?VO
M^CO?Z/%<17^GR:II<%Q-<?\ +I]D]_\ #TQ3_P"(:<.=U^'^8?V_F'G_ .3?
MY'](G_$3%^W[_P \_@S_ .&ZT_\ ^6%._P"(F7_@H#_=^"__ (;C3O\ Y8U_
M.7<:?;323>3_ * _E:??_8O-M;[R+?\ YBUK_H7X9_.F_9K;_GA_X\/\:YL1
MX=Y##^$D_P"O4J'%F/P_?T9_1M_Q$R_\% ?[OP7_ /#;Z;_\L*0_\',O[?Q[
M?!C\/AWIP_EJ K^<G[':_P#/$?I_\33)+>V^1!^Y>3_52>5SW^G^<5R_\0^R
M;LK^O_!+_P!<,=B/W6W]?C^)_1Q_Q$Q?M^_\\_@S_P"&[T__ .6%'_$3%^W[
M_P \_@S_ .&[T_\ ^6%?S@M]CAMIGO+:.PN;<?NI+C5+6>";T_T3_D(=O88X
MJ:UM[:?R41[>\?4#_HLEG^77\?7^M'_$/LK\OO?^9E_;^8+7737[73Y>1_1U
M_P 1,O\ P4!_N_!?_P -OIO_ ,L*/^(F7_@H#_=^"_\ X;?3?_EA7\Y'V.U_
MYXC]/_B:/L=K_P \1^G_ ,31_P 0^R;^[]Z_S-?]>,>M/T/Z-_\ B)E_X* _
MW?@O_P"&WTW_ .6%'_$3+_P4!_N_!?\ \-OIO_RPK^<C[':_\\1^G_Q-'V.U
M_P">(_3_ .)H_P"(?9-_=^]?YA_KQC_Z3_R/Z-_^(F7_ (* _P!WX+_^&XTW
M_P"6%=_X(_X.<_VS-'US2=0\>>"?A7XG\*O=6XU33K?PY=>'/$?V?O\ 9!G!
M/'?IV[U_,5]EA_N?J:E;?))YTTUQ<S?\]+RZNIS_ /JZ<?K4_P#$/LKJ?NZ*
M5_\ *_F_ZW1EB.+,?B-$FUZ;>5S_ %%/^"?/_!2/X.?\%"/A??\ B_X>VTNA
M>,O#&8O'?PHU26U_M:RN"2;.Y.!B]L-0Z*2/8\XW?I+;6(:WAD*&R,T8E^R#
M'^C;B?W/']S'ZU_FO?\ !![XN>(?A?\ \%%/@SHFCZKJ%GI7Q%U/6-&\46<<
MO[C7K;^RL:3:W?7_ )?N_;O7^E3IYD7[<)B?^0C=>5N!SY.4V>O?=7XQQAD6
M'R+,/85&M4VK-76KTM^-_D?I/"6<8J> OUOU3?Z6_4_('_@NI&W_  [!_:/>
M?]\D<-AD=\'7[+';Z_D*_P T.0OYC[WWOYO?\,]^O7O^=?Z8G_!=<_\ &KW]
MI0?],-//Y:]:?XU_F=2??;ZU^F>%E2K]1Q-+:[?EK:-]K=SYCC>O4H5?9TEI
M;^O6]_ZL,HHHK]3J4*<-[M_/_->9^:>__=_$*FDCVV_VK^#[!]JB_P"FVH?:
MOL?]ECU].]0TRXC^V1WD/G>2EQ+J$L48_P"7/_GT]??T&:\_,*$K4/8MIVV3
M>]G;;Y/5GH974I4_K'M;/U/VU_;!^ GP6_X)P? ']E[X<CX,?"OXT_M&_M'_
M  U_X:!^*'Q ^*.C:IJNE:;X/UBT^Q^'_!OA[2;+7--T^ROM-X']H?VF#P3T
M-;/_  3_ /"_[)W[6/Q(^/&FW_[-_P +]*L_!?["GB#7I;.\_M2#0]'^+'@/
M_C[U[2;O_ERL?^)M:>W^AU\[_%_]NOX3_MB?L_\ P3^'7[5?@+XEZ;\5?V;_
M  E;^#O"?Q4^'=SH.N7WCSPO_P >=IH-YI/B>^_L_1;'3@ #W_*F_L=_ME?L
MZ_LK^*/VBGU7X:?%SQ5X)^*G[-WB#X&>'(]#UG08/$=YJ'B2U^QZOKWB&TO;
M_P#L_1;+4?\ J'8(^QU\]6P^:T\!:6(<L7=OW;_S3M9-Z6BXK?H^Y[U#$8"I
M5_>*RZ7M_E\SUG]G7_@FI\8_AE^V9^S9\,?'/@S]G_X]VWQ_^"/BCXJ?#_P?
M)\2[K2OAE\0O"%YX7O+S^U#JPT/4B;[P9P?L'_,5U2SSTY/E?PV_X)6?&[XY
MZ4OQ8\#^)_V</A[X)^*?[0VH_L_>!/#<7Q N[*>'X@6>J7MG_8 %[H9)/^B=
MLG\QGZM\%_\ !5K]F_P7^T!_P3>^+4?PC^+B:7^PE^SIXH^"5UH_A^Y\+_9_
M%/\ PF&DBQM+JS%[?@_;O#E\/[1U;W)-</\ !S_@IY\!/AG\,O@O\/\ 4OAC
M\8-;N?A7^WK<?MAWVJR1>#1!J]O>:]>7G]@VEI]NZ_8;OC\C7BQ7$EO>KR3L
M]KM-\TTNO6*A)IV2YG&^CMZ#_LGNOP[?\.?(?@G_ ()K_M)^,/&'Q1\$W,?@
MOPQJOP?^,EO\ O&=QKGB/_0?^%D7G_+K:?8K'^T+W0_^HCINE_TKY%^+GPT\
M9_ ?XP>*O@YX_P!-\/W/C;X=Z_;Z#XC\/W$IOM#O-/\ [>^QW>J6EY_SX_80
M/\.E?LIX/_X*@_LM^"_C!^TS\=X?@7\7_P#A8GQ8_:ITCXY_#_6/#_BC2YY]
M-\ 6>/M?@W5K36K_ /L[PO>\'_3_  Z#VY&.?S._;2^-7P]_:._:H^)WQO\
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M?$CP5#\,_@OX0^&%U9^+-9M9_#FO#PA;&T^U?V397W''!_M'KV'I];?LV_\
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M/!GQ<UOQ)^S7^U5IW[4$NOZ'=>#;?2M2.CYO+33/]-ON/[.L2-.'IUYS7?\
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M[^P^%_PJ\'_%_P 6^,/"_B/5/$?AS3?"_CS5/L?AZU_T+0SJ'V[4; VFH?\
M(,_Y!5Y^-?G)XX\)W/@_Q9XD\'G5=/\ $\WA?5/[&O\ 4/"]_P"?H<UQ>8^R
M71O+W_C]_P"/O_ZX%?O?\4/VL+/]D#]K;2OVA]+_ &L?B9\;+SXP^ _!_P#P
MCGB3PG\/M"\'00Z/X/U[[%=_#GXA?"?Q/_9I_L/4?"MK:#2?[0TP'TP:^(?C
MA\5/V,_CQ\ ?C3\2-$^!6J?#?]HWQA^TCJ'C?X?>7K-K_P (=_PA^L6O_$V^
MRZ3HO_'E?:=>_P#$PU;3M1'_ "^?\2;I79@_[9]JGB:\FG:S7F^ODE9WOUM9
MG'B*&%I4O:X;#_[3^FGR[]#WW]A_X,? KQI_P3 _X*&_''QE\+OA_JOQ4_9W
MUGP1H7A+QYK%A=?;M-M_$=U97FK:ID_].)N[#_@/7/7ROX5?\$=/VI?C;X.^
M"OCGPOX\_9TMK']H+P=XO^(OP-T^#QU>6'B/Q5X?\'V=U?:M]ITHZ$!HZZ=8
M6PRRY4-N7[RL!SW[,7[<WPB^"_[#?[6G[)?C_P +?%C7O%_[3$6C^5XX^&\N
M@PZ'X;N-'M?^7JTUJ_'VW]1]#7V'^SO_ ,%:/V>/@?:_\$_;G4/AI\:->U7]
MBSX+?%#X87]Q9_\ "&P3^-O^%D6MY9][\_8O[.^U]CW]Z\G'U.(Z=;$?5J\K
M<^E]N7E5E&S=U>ZO9-MNZM9OU\L^H5*/^TI7Y7]^OH_^&Z['YT_!'_@GQ\<O
MCAX3\,>,[/6_AG\/=*^(%UXXTOX57'Q0\6_\(I!\5-8^&_VS_A-]+\$7?V'_
M $S^SA:7?_(1_LO^U:^%]4C?2=0N=*O$V7EOJFH:7_SW@^T65U]C^U<?\N']
M>*_6#7/VV/V8_B]^Q?;?LM_&GX:?&31_%OPO^*'Q ^*'P0^*'POUK0;&;[1X
MPNKR\N],\;_;;[.B?VC]K_L\_P#".], Y[GXS^,GC;]FWQ)\(_@GHGP'^%'B
M#X5_&;0]+U"U^-'C#Q1K']M^%?%7^E8TFTTFTYU WYL?LIU;IU].OTN3/,*B
M7U[F71WVT2UT?5Z*VM]++<^?QM/ 4V_96W?RU?X;'S9(OER>3OCG>//FR6_[
M^#C/_+W_ )[BF5###;1QYAADAF\W-S^]_<3?]/5GSZ]>G3%35]1["GW_ !?^
M1Y/O=.4****UH?N+U:7^8X8BK3_AI6TTWT]3]+_^"0>]?^"C'[*EYOQ]G^)>
MCVOEX_Z>N/\ Z_M7^G9XDBO#?H8;P1(8#A/*SC_2KKOW^M?YBW_!(3_E(7^R
MW_V531__ $K-?Z>?B'_C^7_KD_\ Z5W5?S?XET8XK.?W[LTG)/7O:V_9G[AP
M3:IE]WOU5EY>I^47_!=C_E%Y^TG_ -<;'_T_65?YG4GWV^M?Z8O_  78_P"4
M7G[2?_7&Q_\ 3]95_F=2??;ZU]IX3>_AIO;WY/[^4^5X^_WE_P"%;>@RBBBO
MV&O_ !&?F04445B 4445I:GV7W,G]]_>"BBBHM2_Z!OP_P" ;^TJ_P![_P F
M_P PHHHHM1_Z!OP_X!O]=K=PHHHDC\R.Y0OLS:W$WI_R[ ?Y]?7T+4O^@9_=
M_P  /KM;N31QS330PPK)-=7%U;VMK''%^_FN+RZ^QVG'\OZU^CGP=_X)P2?$
M']I/P_\ LR_%#]H/2/@?\8=;\-P>))%U[P;J<^F:'<>([3[;:>'_ (@[M05?
MM^I?Z(!DJN;SJ!7RW^RGK'A+1_VH/V;_ !#X\2/_ (0:/XE^#XO$=O<'I_I5
MG]D_+ICZ5^@/[5G@OXA^*/\ @HS_ ,%*/L=_;Z5J5QXB\7^+=+EN/%%K!9:E
MX7L[KPW>>"+O2;L]_L-IS_9QS[U\IQ)B*N']A2PF'M>+:DEMT3M:S:;OJ[:6
M>C/4R]_7/XCM\_G_ %;S9\G_ !(_8G\5? OXA?M&?"O]H3Q)_P *K\3_  'T
M&W^P6^G^'+J#2OB1IUYJG_$IU[P[]M_Y<?$=C]DU'U_TPX]:^0)+6]DM4N4T
M35+/38[^XTRQ\S0;JQ@FM[*UL_\ 2OM?V'-[_:/VO_/-?NQXV_;7^'?[;'_!
M-KXA>&/C];>'X_VQ?V=XO 'AWP=XHUB6UN/^%D?!C_A*+*SNK:[.<>)[WP[F
M\R,'\.<_07[<OQA\#^"_V?O#WC_]E_PQ\)O'G[/'Q0_8]^%'AS0?%%M\0=!_
MM7X5_&#P?=F\LKK_ (5/QJ%E?Z=K?VHD<<]SUKY_#YQCZ=7#JKES>Z>CM=).
M_>SOI?M)=+ON^H?]1"MVNS^9BXL=2C5XWTW6+:;O%<:7JEO/W_Y_; ?I^E37
M6AZE:6:7CV>H)#YO_'Q)874$';.;O[#WZGOWK]W/VZ_VI/#'QX_9W_9R_:$\
M)>/-+TK]KKXT?";_ (9]^/'PWLXM!OM#TW_A5FJ69N_C)=Y_XE_@JQ\17UI_
MQ-NW]E7@&.E?HW^T!IO@*;]CG]L#PEKWC_X#^)_&&H?"#]F#QOX7_P"$;NO
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M4W-Q_P ^=Q_WZ%)BZ_Y\Y_R%'UC"?]!*_P#)?\SE^KU?Y7]S_P A]%-S<?\
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M?$C_ ,./K_\ A7[YIT/U_H*?7H4<]SU4U?&337GMTZIO\3SO[$RO_H%7W(_
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MO^A0^)'_ (<?7_\ "C_B&V_X)G?]"A\2/_#CZ_\ X5^^U%5_;N>_]!E3^O\
MMT/[#RS_ *!5_P" H_ G_B&V_P""9W_0H?$C_P ./K_^%'_$-M_P3._Z%#XD
M?^''U_\ PK]]J*G^W<]_Z"ZGW_\  #^P\L_Z!5_X"C\"?^(;;_@F=_T)_P 2
M/_#CZ_\ _$_7_)XK77_!N)_P3?LXY?L/@;XAWBFU\R6VD^(VO?OKFSN;,VGY
M 7?'I^5?O_39>_\ UQ/]:I<09W?7%S?DY*S]=$#R7*[?[M'9]%V/XC?^"M/_
M  28_8__ &1$_8ZU'X+>"?'%M)\=_P!L+X??"OQE'>?$#59P/#^M6K=">I!7
MIUZ>H-?K=#_P;B?\$UVN1/\ \(7X_AU.TN;B87/_  L+7O)F^V#-UZ]NOXGN
M!7*_\' '_(,_X)I9_P"DB'P<_G)7]"P^:^DR.-EM^MR.OOR:]7$<1YU]1PT?
MK=33G>K3;M.*2;:ULFUK:][MW2/&PF3Y7]>Q'^S+7R\GM9'X1_\ $-M_P3._
MZ%#XD?\ AQ]?_P *P?$7_!O!_P $J?"&FWFL>*=)\<>'])TZU^TW>H:Q\5M3
ML;&" <'-W>]LC! ).>,9%?T*5^"W_!QAX>6]_P""4G[4WB![K4-*U3P_IV@Z
MIH^IZ1X@O-)O_(&JV(NK8-9D!1]X[2K%^&4@*0WE+.\Z?_,74_\  [?^VGL_
MV'E?_0*ON1YWJO\ P0 _X)'Z%IZ:SK<7C#1-)N/LYM-3U3XK:I8V5[]LM3>6
MGV.[O<+>DV(R/[//(ZX-4M4_X()?\$@-"@L[S6[S7M'LM0B@NM,O-4^-%W8V
M6L6]Y:"\%SI-U?78%[9&RSG^SFP,?>.17Q7^U7XEEU7]HC_@CE\+/&=YK&F_
ML_77["WQ@^(6F:?)KUU-I7C?XH67P0LKK2;7Q#=XYOM.O0+_ $G))/(&!@#\
M<OV:_BA\:?B]X7_9RTK]I/6-8MO#>A_\$J_VT/%'P@_X2B_NH-*U+Q!H]WXD
M'A[5+/\ Y_=;T[_1-/TG'MS2_MO/?^@NI_X'^MC;^P\J_P"@9?@?TQZQ_P $
M#?\ @D!X=O=,TW7[[6-#O]:MK>_T:TU/XV7-E-JVG7FTVEUI=I>WH-Y9G) O
MU$@SU=0<UHG_ (-]/^"4"ZA9:2VE^.XM7U&TN;_2]/G^)NO07FHPV8S<C2K4
MKF]O-//!L=-4L"0=A&2OY$^$/^"<?QI_;'_8D_8:_;2^*_[4MQ\%M-T3]B3P
MOX"^,FN^/[[58-;\$Z?X.\8ZSK-KXITJU PNM^([ :3I^6QJA-Z%ZD _:NN_
M\%,?AG^S3^TNGQ'_ &D?"7C@_%GQS\+O!_C:V\)7,ER=)_9P_9NUC7O#7PV\
M$ZG:V9&+WXP^--<U;2?%_BW^S\YTD]0<&C^W,]_Z"Y_^!$5,CRO_ *!EYJVW
M;T/LRS_X-P/^"8E];PWEMX1^(\UM/&)89!\1]>Z9'/\ ];'T[&IO^(;;_@F=
M_P!"A\2/_#CZ_P#X5^ZOAB[M+W0-&U"QO;;4;/4+&VOK74;,?N-3@O;<72ZF
MIZG^T=XOO3+#!R>>AI?V[GO_ $%U/_ K_H1_8>6?] J_\!1^!/\ Q#;?\$SO
M^A0^)'_AQ]?_ ,*/^(;;_@F=_P!"A\2/_#CZ_P#X5^^U%']NY[_T%U/O_P"
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M17BG_#0OP1_Z*_\ #;_PK=(_^6%)_P -"_!3_HKGPW_\*W2/_EA71_9^>_\
M0)+_ ,%U?_E0?VCE_P#T$1^]?YGME%>)_P##0OP4_P"BN?#?_P *W2/_ )84
MO_#0OP1_Z*_\-O\ PK=(_P#EA0\OSU;X27_@NI_\J#^T<O\ ^@B/WQ_S/:Z*
M\3_X:%^"G_17/AO_ .%;I'_RPI?^&A?@C_T5_P"&W_A6Z1_\L*/[/SW_ *!)
M?^"ZO_RH/[1R_P#Z"(_>O\SVNBO$_P#AH7X*?]%<^&__ (5ND?\ RPH_X:%^
M"G_17/AO_P"%;I'_ ,L*?]G9]_T"2_\ !=3_ .5!_:.7_P#01'[T>V45XG_P
MT+\%/^BN?#?_ ,*W2/\ Y84__AH/X*?]%>^&G_A9:!_\GTO[/SK_ *!:G_@%
M3_Y /[1R_P#Z"(_>O\SVFF.2=V>T1'X<UXS_ ,-!_!3_ **]\-/_  LM _\
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M=:%:78Y ;0[IM/!Z$@\ YKF_$'["?[*_CWPM\,?!FN_!_P )Z]X/^$_AR_\
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M_17/AO\ ^%;I'_RPI?\ AH7X(_\ 17_AM_X5ND?_ "PH_L_/?^@27_@NK_\
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MGV]?D)_PO'XG?]!O_P BZI_\G4?\+Q^)W_0;_P#(NJ?_ "=7D<?[SS=CQO\
M9^H$O^?PY_ER5W_5<)_T#+_P&/\ \B8O%5^[_P# G_F>N?\ "\?B=_T&_P#R
M+JG_ ,G4?\+Q^)W_ $&__(NJ?_)U>1T4OJN$_P"@9?\ @,?_ )$\YYABM?\
M:5U_F_S/78_CM\2X]^_6(WQZRZIU^HON?>N_^&O[6GQI^&_B32M>\/>-?$&G
M7]OJEO+#>6FLZIY%GUS=&T^W8_E7S'3&C>17A2;R3)^Y^T<_N?3IQT_GS58_
M*LOKTL!2JX96Q>]HI.VSV7:Y?]HXN@\/5I8AM^K[]-=GL?Z07_!'C_@I'J7[
M:?PMM_"7Q'N+;5_BMX'EL(YK^VD\C_A)-!:[-J=?N[08&ZP-L2Q/+'D\YK]X
M:_@=_P"#:#5=1C_:UTW35N=D=Q\*O'^GW5O_ ,]K?1S9W=G=$#WNQ[]*_OB
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M?C_3\?K3]G+]A/\ 8P\4>"_^"<'A[6_V;]/O/$/[7_[+?QH\1>+?%'F^*/\
MB6^,/!^E7=[:71'V[@\]..W%?S>>!OVG/VA_A/\ #_6_@GX#^-OBSP9\-_'$
M6?%O@>WNK6?2KS_K[NOI]>_;BNUT3]NS]L/P_I?@:Y\*_M%?%S04^ ]A<:#X
M)DL[^V^P^#]/O/\ C[M?A[_S^V&HCVX(Z5EB<KQ]5_[+F'U1)MM7:NOJ=DNN
M\M]O*\@]O2H?Q</IWW]?PT/TM^"W[+'[*/Q@_89^-/B'2/ACX3\/?&S]C?XM
M6'_"\[B2_P!>@U7XJ? _1]=O+RTUZT_XGF?MVGWV/#_TLP#BNJ\'_LU_L?\
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MA\92KTG4I8=6_+4_0C_@@9:I'_P5)^&NI167]IZI<?#CXH2ZKJ&C_O['3?\
MBE_^/7/M_7BO@_XC?"OQ5XP_:,_:*U7_ (16\UO1/#?Q:N/B#\0;CQ!I]U!8
M6?A^S\>6=G_97VOU^PW?_P!;U\B^$/QP^*G[.^O_ /">? WXE^)/A7XJU6UN
M-!T?Q)X3U2T_X2JTU"\)^UB[M/3\.?:NM\7?M??M/^*O"?B3PCXG^-GQ(O\
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MZR7TSZ\_C]>]&+C_ )[VG_DI_P#%5[3_ ,,__$+_ * ]Q_X(M2_^0:/^&?\
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MR36>^//_ "U]_P#/\OK*//C:Y>#4K=[;4+K^U+^WN(K7^U9KB\M?L?\ 9?\
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M( RV./7J">_'/%?T)2(LMW(LB(RE[;J#G_CY!Y['^G->C7Q5=8;#VJ5/M_\
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MF0",L*/;8C_GY4_\&U/_ )(/98?^2G_X##_(V/\ A!? O_0E>$/_  1Z)_\
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MS;/7G)!ST-9JO37_ "Y;VZ>G8]!4_P#I_;UM]VQ_(9I?QI^,MW_P27_X(0^
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M8>([*[NAXK.HY_M4D =@9^L4O^@=_<P^KK_H)7H??/P>^)GA+XS?"SP!\6O
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MRW_AY1^Q)_T==\%?_!T/\_\ ZC[9_P L'_A:/Q#_ .@S>?\ ?E:/^%H_$/\
MZ#-Y_P!^5H_XA;A_^ABO_ 8_Y!_KOC_^?"/]4#_AY/\ L2?]'7?!?_P<#_'_
M #@^V6_\/*/V)/\ HZ[X*_\ @Z'^?_U'VS_E@_\ "T?B'_T&;S_ORM'_  M'
MXA_]!F\_[\K5_P#$+\+_ -#%_P#@$/\ (/\ 7?'_ //A'^I]_P /*/V)/^CK
MO@K_ .#H?Y__ %'VR[_AY/\ L2?]'7?!?_P<#_'_ #@^V?\ *_\ ^%H_$/\
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M?]^5KB_XA;A_^AE_Y+'_ "-WQQC_ /H'74_U/?\ AY3^Q+_T=;\&/_!U<_\
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ME<:]:Z/H]_:^'-*O-8L[7[9=Z#I.K:UD?;OL/_ZS7]+_ /P4!_9]\._M!_\
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MG\IWPH_9O^*_Q^\/_%KQ5\$_!EYXST'X,:#K'Q!^(VH1ZS:P0:#X/T?[8?\
M0^/]-_L[''?%>%+<Z5&TVI)<^=H^H:K<_P!EQBZ^W3V>G7EK9_9+6[M++I_I
MWVOT_"OZD_V-K;]GRX/_  4DU7]FOP-\3_!]M<?\$HO$-K\2_#_BCP'=>#K'
M0?BQHPO='\0VH\/7M]R=1-G=>(#[7A(]*/@O^R_^QOXP;_@ESX/F_9R\!W.E
M?M@?L>>*/$?Q>\87<.J?VKX5U?PUI5W9Z3XRM,G&C'3K_//']JYZ<9K:GQ]B
MOK;PV.PSLGNHO^6^NGW675;[EU,CG"G?3YVOO;??\=#^6F:W>U_<WMS]IO\
M2[K[+?V^EVMU!]MS_IEI=?Z;C_D(X_L^A=DTEY^^C>'3^;JST^ZNIM<TW4+S
M/V30?$/.?_!=QQ7]#^G_ /!/_P" /BC]B_QLGP$?X;ZK\=?@)I?Q T;X\6_C
M"75(?%6L> /^$RO;/P]\4/!'Q"O1_9UE??8?LA_X1_\ LS5.3Z]?8/BG_P $
M_/V:M-T7]IOX=:/X+_X1/2O@!^PS\)_VKOA+\;)+JU@@\=_$B[M;3^UCXLNQ
MD>)_].^UZ>-/..?RKT7Q?A[/W)=OA>[LE]G;WEKVN^CMR_V.O+;NC^73[0D;
M>2\UG>7.H2_;]&M]'U2UG[G_ (I?5NGV+'\J]4^%_P &?'_QL\<Z)\*_AI;1
MWGQ%\6_9[7PYH>L7X@@_M&\NO]+^UW>?^8=_R#J_JA\#_L$_LA>+]'^%?@#6
M_@#X?M=;^,G_  3!\;?M->+?%FCVMU8S_P#"R?#MNHM->TJT_P"7*^U'=G^S
M_3GGH?YD?V1_[4L_BQX,U+P];>);#7M/\.ZAXHT&XT_[7!JMGX@T>U-Y9W7M
M_P >F?PZ5P4^(/:N22=XZM6?VG/EV77E?FK:I/18_P!G->GKVMY^:*WQ$_9C
M^-_PS^+\W[/WB?P?<:;\;[CQ'I_A?0/!%Q+=P?VEJ&L?\>>J?]>./M?^>:T/
MV@OV8_C'^R_X@T[P?\<O#=GX&\6_9?[9ET>/5/W]Y869_P"GW&?^$C_Y"'\Z
M_H+_ &T_B9\.OV@_@G^PM_P4WTK4;-_VC[S4_#W[//BSPYI_V7_A*;SQQI'B
MC2+.U\8VEIG-[_9EB+HZMP% OE [X^E?VQ_V2_!W[5__  5K_:&C^(NE:GK<
MWPG_ &#/"'Q0\.>!]3B\^?QMXHM/!QL[32_"FD\?VU?Z???Z>=/T[JUGCKUP
M_P!9:Z^K*M%QYE/F^)6E%QC97BFXMRTDUM9];F_]EJI_#MTMMKOV[=C^."2W
MAFM4G2:XLX=0E_M2U\0W%_:_V'IO_4KW?/\ Y4#^@-?6/_#!?[5$WCSX8_#1
M_ 5G#XG^,'P^N/B#\.;>W\1VL']L>'[.U^V?:KO5KW_B7X_[!P_^O^K?PL_9
MX_8H^+NA?ME?M#_##X1^/?$7B']FC]B3PO?6/PH\;_#G4_"O]K?&_6-<OM(\
M0:MI/P]-_P#Z:/#QL@O'.;X9X!K](]8^%_ACXR?M4?\ !(7P'XS\#:A8>$O%
M/[#.L7^H>$[>35-#@\*ZS_8%W>?:K75K+_B869TZ^M/^0?\ S'7H_P!;/8-J
MSNFDTU+JN96;5GH]U>VSU5A_V14_Y\?BO0_C6U2SFT'5M5T?6/\ 1K_P_JFH
M:#K-O]J\C^S=0L[O['=W7_3[_IW_ !+\Z=[^]97VBVM]EG-<QW.L64UO=7]O
M]J^PV(T\_P#'W:XO/^/+^SO]$]C]LYK^@G4OV<_V>/V:_P!E?X._M-^._@)X
MP_:0\-_'3XV_M'^ _BK<6\NJ7WBKX>Z=X0U_6='\$:7X3N[*Q'V(?;K/^T/[
M0\1?V7TKW_\ 9C_X)T_ 'XE_ &\_X3;X ZYX5L_B!^R#\8/B_I^J?$2*ZU3X
MFZCXA\-W7VSP]=7>KV7_ !+Q8_8?LG_$OT[\?=U.,J?LGUU:V>ZZ;=W9A_9%
M3_GQ^1_/-\0/V<_C9\*_A[\*/BIXS\ :[#\.OBQ%J$O@CQ9;W]K/!KUO9W7V
M.[NKO_GRL=._Y"'^>.>^%?PC\>?&#5'T3P-9_P#"0S6&EZA+XM\26\MT/"O@
MG1_M7^B>,M6N\\&OV5_;:TO6)/\ @DU_P3!N;S^W/.N-4^+'A>+3]+L+J">'
M3_[4N]8M-+S>_P#'E_H/_$O_ +0ZFOI+_@F/\$/#?[)?P/\ @U^T3^T5H\GB
M_P""/_!2O2_%_P"S]JFG^ ]&NM5T+X#^'[.Z^Q^'O%'C:[T:QU+_ $[4=<L[
MS3\@:6-)%GZCB7Q#.EAHXFM?WY<L5UD[.7+%=^52=M/A>HO[(J6;]ALF^A_/
MA\7/@'\5/@?XVNOAI\2_#&L>'O'-O%;ZI:R1R_\ %':]X.^R_P#(T:3=_P#(
M0ZG\.W%>5^7;,!Y)O/)',7VB7]_-_P!/77'_ -;KZ5^VO_!5_P#98\>?!B\U
M._\ VAM+\<?$OXNZH2/A#^T'X?U^ZTKX'?\ "B!Q::!:Z396.I?Z>+$VG_,2
MSR>Q%?B@75HX?)S]F^RV\5KB7S_]'^R_Z)_];T/O7OX+-:68)/#6Z-=5]_JG
M]SO:S2\1JS:[7_-D7V:/U?\ [^K_ (4?9H_5_P#OZO\ A4M%>VO:Z^U_K;^O
MN/,K_P 21%]FC]7_ ._J_P"%.CC2,C8]PB?\\S+^X]L\]>?KZ=J?15]?WMOT
M\OUVZG-4]K[/]UVT]/S^\^WO^">NL7GA_P#:&^&TVC7MQ87.E_%7P?KUA<1R
M_OX=0^U6=G]J[_\ @OX]:_U6]#51IMM<J )M0AMK^]<,0)KVXM+<SS8&<;RJ
M_EP,8K_*(_8323_AH3P3^\_YJ#X/_P#3I9__ %Z_U<M!C8:/IG(/_$MTTY/J
M=/M<]O7-?A/B?AUEV/PU=*]/%*3BM%>R3W:Z;^NI^I\'?67@-;^=M[W?G]YX
M#^VS_P FH?'_ /[)#XQ_]-9K_*'^*7_(\ZI_UZZ?_P"FRO\ 5X_;9_Y-0^/_
M /V2'QC_ .FHU_E#_%+_ )'G5/\ KUT__P!-E>QX4?#B?6/_ *2C+C_^(O1_
MH<#1117['7_B2/S0****FG]KY?J=F&Z?UW)K>Y>U_P!)MG-M=1W]O+YD>//F
MZ_C_ #]Z][\2?M0?'[Q1HO@SPKK?Q(G\3>$OAG-;V'PTT?Q!%Y^E> ]/%U]L
MN]4TFT_Y_A??9!^E?/U2'_5S_A_Z$:X\1EZJN[2?6^GY^?DSJJ.I4_=4G]S^
MYGU%J'[;W[5TOCZ\^*#_ +07C3_A,]4TNW\)7_Q ^U^1KG_"'?9?['NM+U:[
M_P"@)_8=4O\ ANK]J[_A)? WBN']HWXF?\)/X+T;Q!X(^'/B"35+J":S\/ZQ
MC_2K3_J!ZCQ_I]=__P $U]#T?Q3^W%^SEX;\0Z5H>O:#X@^(.GZ-KVC^*+7[
M=H>I:/K'^AW=KJUIZ?8<?EZ5^[/[4G[-OPUC^'?_  5"?6]$\'>.-'^"?CRW
MTO\ 9AT;X/\ A&V_X3_]G:>\M#]KN?B9]B(Q\+-WUR 1C)R/FL;B,GP5;V6*
MPU^ND4]FEKLM-]7?E3:NU9^K@<!CO9/_ &CTN]M'W?78_G2\/_M??M,^&]-T
MWPEX/^,'BS^RO"WBBX\;^"-/TKQ)JE]!X5^(&L?\A;QY]KLO^/+.;OUQ^)K5
MTO\ ;._:NT>SO(='_:$^(FG_ /"0?$8_$;5)+?Q;="Q_X6!H]K]CN_%'_<1Y
M/?FOTV^+/[ 7QP^/NB_L(>%?#1^!VD>';O\ 8Y\7?'"7XD?#WPEJGAKQ3J?P
MI\/6RW=SKOQ6TIKT"_OV9@HQG+G8,MP.1_9(_P""5\/Q6_:8_97\ >)_BE<Z
MA\$/VD/ 7BCXH>#?'\GA+^R?[?L/A7H/VSQ#:BTO<?8L&T_L_G@#OC.,/]9.
M&/\ H%CIO[E[6NME%OH^FMG:Y+P&:]W]_P#P3\Z&_:P_:EN+/XHV"?&WQ8EK
M\0/%']O>-].M_%&JS_\ "5>.+/['>VFO:M]?LGTZ>M<9\5/C1\6OC5XPA\<_
M%KQ/JGCWQGK$6CRRZQJFJ:I>SS:/9Z4;/2;7%[]#^'MBONKX9_\ !-/Q#^T1
M#XM^+O@#QS;Z;\(M0_:"U']F[P'>:AHW[CQ7XH_M36+.[NOM?V[3<?V=_9-I
M_P"!E,T/_@EWXM_LO9\;/C3X/^"WB37/&_Q(\$?#G5/%%A=:'X4U*X^">EWO
M_"66MWXA^W?V=C4=<M/[/TG_ *_#GV[?K^1*D\12PR^Y+3[KD?V?CO[WXGQ?
MKG[6'QU\4:3X&\)^+?B=XHU+0?A?]H_X5IH_B"ZM;[0_!_\ S]W6D_\ 8./\
MZZB;]MC]J6^^)%G\;[SXZ_$#4/B=X/T'1_#FC>-#XMU0ZKKVCV?_ #"]6N_^
M?'3O^HB>>.*_<2#_ ()_^%OVM?V#O^"6/A+PEJ_PX^!_QO\ BA<_&^VUWQ#X
M?TL:X/B'!X$N[W[+<_:QS_Q,/L8/(P<\$D''YZ_!7_@E=J7Q@^$=G\8/%OQI
M\#^ ]!U#]J#4/V:=>T?RC_R.%G=7=G:9_P"PC]E'&.>W>N;^V,BQ*=6KAK?5
M&UK&VJ=DUIJGHTUHTS:AA\PP^EW][Z_/M^1\0?\ #7'[5TGB;XD>*K/XX^-+
M"Y^,%I_PB_Q4U#2Y?W_C;1]8NO\ 2]!S>\G^SM#/L/KBOOC]HO\ X*0^'/%?
MP0_9(^'O[.=U\6_A-XO_ &9/@QK'PF\5^,-7N-+L(?%.G7EPHM=*TLZ,Q^R'
M46NKTYU *,$+M)4N_)ZQ_P $N/BYX./[3[?%'Q[X:\-_#7]DCXJ>$/AUK/BN
MS_U.L:QX[N[(>'S@]0+&\LQ[9 ZFOMSX0_L27_P(_9X_X+(_!_XR^#?!_COQ
MS\-/@3\,/'?P7\9ZA#F?3Q\2)K8^'KFSNR1]B.H&ZM&)'/RD$8SCGEG'#DZ:
MQ]7"\SP<E:UK^_*-.[5U=1512:>R5TKN*?33IYAB/W3KM>M^EW^-OT]/Q/M_
MCQ\7=/\ "_B'X73?$[7)O"NL6OE:]I]O?W4^K:];WFJ?;+OPOJUW9'_3;'[=
MVQ5G7?VC?CEXB\%P^ /$/Q:\27/A*WL+?PO?Z5K-_P"1]L^&_AO_ $S2?!EV
M.@L?MUWUY/X5]F>*/^"2?QN\(Z#X_P##=AXJ\%^(?CC\!_V;O!_[2/Q+^&?^
ME>?>>'_&%U9W>E9^Q=]-^U'4.PX_+TC4/^"0^L>"]*^*]YXV^//A_P -^+?A
M/^S3X0_;(^*OA>#P'JGB.'3? _B.UYTNTN_MW^F]R?I@]*ZO]8N&'MAUKMHN
MMK=.[7X=U>G@<PUUEU_4^!H_VT/VM+>.PO--^-GC6PN?#_@/4/!N@7'_  D>
MJ?:--^$]Y_H>K> [2T_Y?;'[!G_D'?2O'_"OQ \3^!]4F\5>#/$-Y#XD_L:W
MU2+6-0NO/@_TS_F W=W>_P#'E_H/3^T3Z=J^^?BY_P $YQ\*_#/[.?Q+O/CE
MH>J_"+XW_!OQ1\6O!'QDC\&Z]]A\-:?]E&=!O/\ 3O<<?X\]G_P2(_9)^%W[
M7G[0GBV\^,UG_P );\(OV?\ X2ZQ\7]>\"6\5UX<M_B0=(MKS^R=4M+3_D(W
MMC_HF#I_';)';?\ M?)?8^V45O?:/>UK\O1Z>NFAYSR_'7^UUZOS\S\RO^%B
M>(;>ZL+G2O$FJ6#^%_$=QXR\+R7%U_Q*O"NL^)19WFK75I9_]1&^M.OI7ME[
M^VQ^U7>?%/PQ\=+_ .-GC"Z^,?@__B3:#XXT_5+J#7+/P_9VI_XE?VNR_P"/
MVQU&Q_XE_P! ?6O4O$G[; USQYXUU+Q5\-/ 'BKX/WFO>(/#GPZ^&Z>"=+\.
M3^'+?[5>:/X3M1JUD/\ BIN.#D_\2GU'2O:(_P#@DQ\=?[#30G\;^#K7XZW/
M[/&L?MAQ?!O3S_I^F_#B\N\6EIQ_T#[(D =>WM0\1E5?]XU%:;/E5UUWVT>N
M^_FKQR9I3O3N]+=_S_KYGQ#H_P"UQ^T?9_$#6_B[IOQL^(EGXG\4:7K'A+7I
M/[>NX/MEOK%U>7GV6[M;+_B7?\O?X?AFNJ_X;<_:QL_%'@/QRG[17Q4?7O!^
M@ZAX#\!ZA>:]]NGT&WN[O_D%_P"A?\>6+'[7Z_X_*D,DEY;Z5<[[>VL]4L;B
M6_S+_P >>L6=W]BN^?\ (X_/]2O^"/>E^'_&7_!2G]EKX;>.-$T[Q!X'\;^*
MM2MM8TCQ3X<M9[?QK<CP7XEUFSNCV']FFT&2<XQ^7+CL3E6&H2KU<-S*$92:
M2BW:,92T\VHNU[*[W6K12>:U*OLKM;=6NJ\^Y\H^&_VL/VHO OA7Q?\ #KPK
M\;_B!8>'OBAXM\0:[XR\/ZAXCNO^$<U[4/LOV.[NO[)'-E^!ZU-H?[=G[76C
M^%_!.@Z/^TA\1+/0/#_@W6/!&EZ';^*+J'2M-\/ZQ=?\3;2[2TO;X?8CJ7^<
M4?M@7$%]^U=^T)80_P#$DTW3/V@O'/@W2[?PWH-K!I6CZ/9^*+S1[2UM.?\
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M>:GK+_WZ_P#K5D!+147FIZR_]^O_ *U'FIZR_P#?K_ZU $M%1>:GK+_WZ_\
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M_2/ZIOVG/CY\'_'7[-'[9/AN']H?P'JOB?QC^W]X0^*OPODU#Q1Y^N6?P_\
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M -^O_K4>:GK+_P!^O_K4<]3L_N9'U>GY?C_D2T5%YJ>LO_?K_P"M1YJ>LO\
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M0 ?9X?\ GFOZ_P"-'V>'_GFOZ_XT44 'V>'_ )YK^O\ C1]GA_YYK^O^-%%
M!]GA_P">:_K_ (T?9X?^>:_K_C110 ?9X?\ GFOZ_P"-+Y$/_/-/^^1116^'
MU6NNGZ(TI]?E^H>1#_SS3_OD5!Y47]Q?RHHKMII:Z+I^IH'E1?W%_*CRHO[B
M_E116@7?=_>_\P\J+^XOY4>5%_<7\J** )OL\/\ SS7]?\:/L\/_ #S7]?\
M&BBO-K_Q&8U>O^'_ ##[/#_SS7]?\:/L\/\ SS7]?\:**Q)#[/#_ ,\U_7_&
MC[/#_P \U_7_ !HHH /L\/\ SS7]?\:/L\/_ #S7]?\ &BB@ ^SP_P#/-?U_
MQH^SP_\ /-?U_P :** #[/#_ ,\U_7_&C[/#_P \U_7_ !HHH /L\/\ SS7]
M?\:['X=:-I5W>V'VFPMIOWW_ "TC!['_  HHIO\ A8G^NC-\/M\OT1_>=_P0
M9\&>%- _9;\=>-=&T#3-/\6'53IY\06]LBZG]B"EA;_:3N?RP0#CKQUK]Z-7
MT^RO9K:XNK>.>>33[$O(^=S'R%/."!U)[445_+_%S;SG&7;=JME=WLO9P=O2
1[;MW;[G[WP5_R+UZ/_TH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Y 2H# 2(  A$! Q$!_\0
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ME474M+N+74+:"=TM;F.WNU1H+R&XMY)(F\J_X(@7-S=?\$M?V1Y+JYN+J1?
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M"YEFDJ\:^6Y5_:.*C/$99+"8FEBZE*ACY5J<:/LW_+M^Q+_P44_;._9:\/\
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M&+_^W?'>MZBO]I6EG;:$M^;'0-)L;&WFL;C5=*O6O);FY@G-EM0BON3]LO\
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M4]0N_ &O06=AIUC;))<7E]=SR1P6MK CS3S2)%&K.P!^6?\ @C!X4\4>"/\
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M7U)/-244 4+C3+*ZGCN9X$DEC#!&95.-VW)P0>1M7![8%7P   .@&!]!110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $3 2P# 2(  A$! Q$!_\0
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MS#S_ /)O\C^C[_B)B_;]_P">?P9_\-WI_P#\L*/^(F+]OW_GG\&?_#=Z?_\
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M-\ 6>/M?@W5K36K_ /L[PO>\'_3_  Z#VY&.?S._;2^-7P]_:._:H^)WQO\
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M?$CP5#\,_@OX0^&%U9^+-9M9_#FO#PA;&T^U?V397W''!_M'KV'I];?LV_\
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M/!GQ<UOQ)^S7^U5IW[4$NOZ'=>#;?2M2.CYO+33/]-ON/[.L2-.'IUYS7?\
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M[^P^%_PJ\'_%_P 6^,/"_B/5/$?AS3?"_CS5/L?AZU_T+0SJ'V[4; VFH?\
M(,_Y!5Y^-?G)XX\)W/@_Q9XD\'G5=/\ $\WA?5/[&O\ 4/"]_P"?H<UQ>8^R
M71O+W_C]_P"/O_ZX%?O?\4/VL+/]D#]K;2OVA]+_ &L?B9\;+SXP^ _!_P#P
MCGB3PG\/M"\'00Z/X/U[[%=_#GXA?"?Q/_9I_L/4?"MK:#2?[0TP'TP:^(?C
MA\5/V,_CQ\ ?C3\2-$^!6J?#?]HWQA^TCJ'C?X?>7K-K_P (=_PA^L6O_$V^
MRZ3HO_'E?:=>_P#$PU;3M1'_ "^?\2;I79@_[9]JGB:\FG:S7F^ODE9WOUM9
MG'B*&%I4O:X;#_[3^FGR[]#WW]A_X,? KQI_P3 _X*&_''QE\+OA_JOQ4_9W
MUGP1H7A+QYK%A=?;M-M_$=U97FK:ID_].)N[#_@/7/7ROX5?\$=/VI?C;X.^
M"OCGPOX\_9TMK']H+P=XO^(OP-T^#QU>6'B/Q5X?\'V=U?:M]ITHZ$!HZZ=8
M6PRRY4-N7[RL!SW[,7[<WPB^"_[#?[6G[)?C_P +?%C7O%_[3$6C^5XX^&\N
M@PZ'X;N-'M?^7JTUJ_'VW]1]#7V'^SO_ ,%:/V>/@?:_\$_;G4/AI\:->U7]
MBSX+?%#X87]Q9_\ "&P3^-O^%D6MY9][\_8O[.^U]CW]Z\G'U.(Z=;$?5J\K
M<^E]N7E5E&S=U>ZO9-MNZM9OU\L^H5*/^TI7Y7]^OH_^&Z['YT_!'_@GQ\<O
MCAX3\,>,[/6_AG\/=*^(%UXXTOX57'Q0\6_\(I!\5-8^&_VS_A-]+\$7?V'_
M $S^SA:7?_(1_LO^U:^%]4C?2=0N=*O$V7EOJFH:7_SW@^T65U]C^U<?\N']
M>*_6#7/VV/V8_B]^Q?;?LM_&GX:?&31_%OPO^*'Q ^*'P0^*'POUK0;&;[1X
MPNKR\N],\;_;;[.B?VC]K_L\_P#".], Y[GXS^,GC;]FWQ)\(_@GHGP'^%'B
M#X5_&;0]+U"U^-'C#Q1K']M^%?%7^E8TFTTFTYU WYL?LIU;IU].OTN3/,*B
M7U[F71WVT2UT?5Z*VM]++<^?QM/ 4V_96W?RU?X;'S9(OER>3OCG>//FR6_[
M^#C/_+W_ )[BF5###;1QYAADAF\W-S^]_<3?]/5GSZ]>G3%35]1["GW_ !?^
M1Y/O=.4****UH?N+U:7^8X8BK3_AI6TTWT]3]+_^"0>]?^"C'[*EYOQ]G^)>
MCVOEX_Z>N/\ Z_M7^G9XDBO#?H8;P1(8#A/*SC_2KKOW^M?YBW_!(3_E(7^R
MW_V531__ $K-?Z>?B'_C^7_KD_\ Z5W5?S?XET8XK.?W[LTG)/7O:V_9G[AP
M3:IE]WOU5EY>I^47_!=C_E%Y^TG_ -<;'_T_65?YG4GWV^M?Z8O_  78_P"4
M7G[2?_7&Q_\ 3]95_F=2??;ZU]IX3>_AIO;WY/[^4^5X^_WE_P"%;>@RBBBO
MV&O_ !&?F04445B 4445I:GV7W,G]]_>"BBBHM2_Z!OP_P" ;^TJ_P![_P F
M_P PHHHHM1_Z!OP_X!O]=K=PHHHDC\R.Y0OLS:W$WI_R[ ?Y]?7T+4O^@9_=
M_P  /KM;N31QS330PPK)-=7%U;VMK''%^_FN+RZ^QVG'\OZU^CGP=_X)P2?$
M']I/P_\ LR_%#]H/2/@?\8=;\-P>))%U[P;J<^F:'<>([3[;:>'_ (@[M05?
MM^I?Z(!DJN;SJ!7RW^RGK'A+1_VH/V;_ !#X\2/_ (0:/XE^#XO$=O<'I_I5
MG]D_+ICZ5^@/[5G@OXA^*/\ @HS_ ,%*/L=_;Z5J5QXB\7^+=+EN/%%K!9:E
MX7L[KPW>>"+O2;L]_L-IS_9QS[U\IQ)B*N']A2PF'M>+:DEMT3M:S:;OJ[:6
M>C/4R]_7/XCM\_G_ %;S9\G_ !(_8G\5? OXA?M&?"O]H3Q)_P *K\3_  'T
M&W^P6^G^'+J#2OB1IUYJG_$IU[P[]M_Y<?$=C]DU'U_TPX]:^0)+6]DM4N4T
M35+/38[^XTRQ\S0;JQ@FM[*UL_\ 2OM?V'-[_:/VO_/-?NQXV_;7^'?[;'_!
M-KXA>&/C];>'X_VQ?V=XO 'AWP=XHUB6UN/^%D?!C_A*+*SNK:[.<>)[WP[F
M\R,'\.<_07[<OQA\#^"_V?O#WC_]E_PQ\)O'G[/'Q0_8]^%'AS0?%%M\0=!_
MM7X5_&#P?=F\LKK_ (5/QJ%E?Z=K?VHD<<]SUKY_#YQCZ=7#JKES>Z>CM=).
M_>SOI?M)=+ON^H?]1"MVNS^9BXL=2C5XWTW6+:;O%<:7JEO/W_Y_; ?I^E37
M6AZE:6:7CV>H)#YO_'Q)874$';.;O[#WZGOWK]W/VZ_VI/#'QX_9W_9R_:$\
M)>/-+TK]KKXT?";_ (9]^/'PWLXM!OM#TW_A5FJ69N_C)=Y_XE_@JQ\17UI_
MQ-NW]E7@&.E?HW^T!IO@*;]CG]L#PEKWC_X#^)_&&H?"#]F#QOX7_P"$;NO
M?_"*S:AX;M='&K6OA/\ TX?Z=]A^U_VKJ&/[5(P1I..:]'^W\5M_8TD]5:SZ
M73[76SOL[Z"_L]?]!"_$_G=_8<_8GUC]L?6/CE9Z=X_O/AMJ_P '_@YXX^/D
MNH7GA>Z@L=>T?PA:_8OLEGFQQUN\?YQ7POI^CZWKFFRZPFCZH\UG:V^J17D>
MEW7D7FC\?:]4^R65C[=QVK^U_P +^-/!T?[27Q@^('PU^(_P>T/]D3QI_P $
M>[GP;\+_  _8^)/!VB3:;\5O[$M+.YTR\TK[:NHWNH&[^U%@,@,2 6P&;QC]
MAOP_X8\)_LV_!"Q\<_$CX'ZWKWCC]C+]H#PEHW@S1Q\.?"M]_;'_ !.+S_BM
M]6OM<_M WWV[_D$\X'X<>92SRNZTG6RYQBU%I.+33?/S)[W:M&ZZ7Z\VG7_8
M].W_ ",%][\O,_EZ\8? OQ;X3^%WPZ^/'AN\_MCX7?%#^V+7PY<]K/6/#?V/
M_A(;6[Z&RYNZ\0B_>,ES)\CR_P"MC_KTQWK]B+B/2/#?_!#CX@Z'K?V>TUWQ
M!^W+8:S\*K>WOS?07MAX<NKS_A+/^$>N\?Z;8Z=SSIWJ/>OQZD_>:I?S0_ZG
M4);C5)?^OG^F?3&/YU]UE%>EB<"ZCPK33M[R6NB=UIMJTMG>+T[^3B*?U>K[
M+ZQ?^O\ @?B/Z?['Z8_GU_K6EHGB#Q5X?DLTT>_\4/J>H1?ZO3]4_P"$<L=2
MM^?]*N_\XY],UFT5Z5J7_0-^'_ ."IB:M/\ KS_49=:A]HU*]FO?$-QK%YJ$
MOFRZQX@U2ZUR>SN+/'_$K^U\\_K2*UU')<WC0Q6U_J'[J_CMY?W$UO9G-I='
M'?H?I4NU/2+_ +]?_7I*=J7_ $#?A_P#'ZY+L_O?^9#',D?^C;/FD_#MZ?U/
MIQBIJ**+4?\ EYAE]R>G],CZW5[_ (L****7[GM;_P !.;$/ZQTMV[_A_7YA
M111094Z?LZ7W[MW\MV%%%%#V?H_R9H?IE_P2$S_P\*_9;]?^%J:/T]?M?:O]
M//Q#_P ?R_\ 7)__ $KNJ_S#/^"0F?\ AX5^RWZ_\+4T?IZ_:^U?Z>?B'_C^
M7_KD_P#Z5W5?SIX@_P#(Y?I+\T?O'!'_ "+EZ'Y-_P#!>0_\:O/VEHD=[-?[
M%TZYBO/]=_I']OV9/7GU'.:_S1+A?+D79A_]%MY??BU/'Y#'^ K_ %D_VW_V
M>(?VI/V4?C3\"+J6.!_''A*X@T:4VWVX6E_:7(OK,A<_Z82UJ%P0&_TLYR,9
M_P L/X[?!OXB_ #XF>,_AO\ %'PKJ'@_Q)X7UFYL)=/O(KKR)M/_ .83=6EW
M]AZZC8_9-1QS_6OI?"_,,+AJ<J56T7S+=I;I6>K6_P"GJ?,\;X:M7J^TI)V2
M[/\ R>VYY%14,=Q)-O1+#4$>/_6^9:_N/^W3Z>W/\ZDS<?\ /G<?]^A7[-B,
M5A'55L2N]TXZ=>Y^:?5ZO\K^Y_Y#J*9BZ_Y\Y_R%+FX_Y\[C_OT*Q^L83_H)
M7_DO^8OJ]7^5_<_\AU%-S<?\^=Q_WZ%)BZ_Y\Y_R%'UC"?\ 02O_ "7_ ##Z
MO5_E?W/_ "'T4W-Q_P ^=Q_WZ%)BZ_Y\Y_R%'UC"?]!*_P#)?\P^KU?Y7]S_
M ,A]%-S<?\^=Q_WZ%&;C_GSN/^_0H^L83_H)7_DO^8?5ZO\ *_N?^0ZF21I(
MNQ_N?Y'_ .NC%U_SYS_D*7-Q_P ^=Q_WZ%'UC"?]!*_\E_S#ZO5_E?W/_(22
M/SKA+E\?:8[JWOXI(_W'DW%GS:77KQZD=:[GXB?$CQ)\48]'N?%NMWFJZQH^
M@Z/X2BU2WE-CJLWA_1[7[':6NK7=D/[0UKO_ ,A#UZ]37#8NO^?.?\A3+>WD
MM[J:Y>SN)DDZ1]_T_P .*QJ?4,1_&Q"?W-_GH=V'5;#[)]]+_D,:SL)(8884
M\F&.6WNHO+SY\/V+_I[_ .?'_J']S3UM;..]34(+:W@N8[^WO_\ 1[4P037%
MG_QZ?;+3!^V\4_RYA]RSN/KY1S_G'OWZ4]H[S[.SPV<CW'F^5%;R?N//X_ =
MCS[_ )1R970_>)Q?;X=]/-]SK]O5[O[G_D4VT^S:W>S\G9;R2ZA++''^X^V?
MVQS=VMWG_C\L1_T#_>K/DP^9<R;(_)O/[/,MF8@=*_XE'_'I=6FD_P#(/LK[
M_P"O^-F.WO%U#^S;FSN$N8[6WNKK[%%]N@AGO.EKUZ_XT^2SN8[7[9M_UMKJ
M%U:V_P#RWFN+/_EUX^G;'X5TU*F#ITO:U.77TV?EWL[F,,96J5?94KM]=]-S
M*DT^SDC='MHW0G_EIC]S_P!.MI_SY6/3CZ&IOL]FODO<VT<WV:_M]4M9/*_?
MPW%G_P ^EW_SXG&?[/I^+K_GSG_(4&.9O^7.X('<0G_ UQ^PRMZ_6(]]UUU,
MOK&.OOU[/N=YXL^*/B?QUX;\#>#-5UFXF\)?#?[1_P (;X7M_P#0=#T'[9_Q
M]W5II-E_Q+_M^H_]!#FN#AC2W5TA^1,?ETZ?AC\.N*9';O'O\NSN$]_*Y]OS
MZ?X5/MNO^?2?_OT/\*Z:=7"4_P!U2Q"MY<MM/G;8I*M4_>U4_N?2UNGS$HHV
M7/\ SZ7'_?!IN;C_ )\[C_OT*OZQA/\ H)C_ .2_YF->E6?1_<^OR\_7SU'4
M4W-Q_P ^=Q_WZ%)BZ_Y\Y_R%'UC"?]!*_P#)?\SE^KU?Y7]S_P A]%-S<?\
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M?$C_ ,./K_\ A7[YIT/U_H*?7H4<]SU4U?&337GMTZIO\3SO[$RO_H%7W(_
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MO^A0^)'_ (<?7_\ "C_B&V_X)G?]"A\2/_#CZ_\ X5^^U%5_;N>_]!E3^O\
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M^A0^)'_AQ]?_ ,*/^(;;_@F=_P!"A\2/_#CZ_P#X5^^U%']NY[_T%U/O_P"
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M17BG_#0OP1_Z*_\ #;_PK=(_^6%)_P -"_!3_HKGPW_\*W2/_EA71_9^>_\
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M3_Y /[1R_P#Z"(_>O\SVFF.2=V>T1'X<UXS_ ,-!_!3_ **]\-/_  LM _\
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M=:%:78Y ;0[IM/!Z$@\ YKF_$'["?[*_CWPM\,?!FN_!_P )Z]X/^$_AR_\
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M_17/AO\ ^%;I'_RPI?\ AH7X(_\ 17_AM_X5ND?_ "PH_L_/?^@27_@NK_\
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MGV]?D)_PO'XG?]!O_P BZI_\G4?\+Q^)W_0;_P#(NJ?_ "=7D<?[SS=CQO\
M9^H$O^?PY_ER5W_5<)_T#+_P&/\ \B8O%5^[_P# G_F>N?\ "\?B=_T&_P#R
M+JG_ ,G4?\+Q^)W_ $&__(NJ?_)U>1T4OJN$_P"@9?\ @,?_ )$\YYABM?\
M:5U_F_S/78_CM\2X]^_6(WQZRZIU^HON?>N_^&O[6GQI^&_B32M>\/>-?$&G
M7]OJEO+#>6FLZIY%GUS=&T^W8_E7S'3&C>17A2;R3)^Y^T<_N?3IQT_GS58_
M*LOKTL!2JX96Q>]HI.VSV7:Y?]HXN@\/5I8AM^K[]-=GL?Z07_!'C_@I'J7[
M:?PMM_"7Q'N+;5_BMX'EL(YK^VD\C_A)-!:[-J=?N[08&ZP-L2Q/+'D\YK]X
M:_@=_P"#:#5=1C_:UTW35N=D=Q\*O'^GW5O_ ,]K?1S9W=G=$#WNQ[]*_OB
MQP*_G#CG+<%E>?8G"8&A]6PZ2E9N[N[INW1.S2^;/VKAC$XG&8#VN)=]%N_3
M6]_ZN%%%%?'GTX5G7'^JB_Z_X/YFM&LZ\Z0_]?\ !_*I7^]+T_1F3_W5^C_)
MG^=I_P '$G_)YWQ,_P"NGA;^5W7\]T'^I?\ ["MS_(5_0C_P<2?\GG?$S_KI
MX6_E=U_/=!_J7_["MS_(5_4O"/\ R(,M_P ,/_28'\^Y_P#\C3$?XO\ ,NT4
M45]*>,%%%%1/;Y_HSJPG\3[CV#]GNX\)6_Q^^"#^/'MT\#2?%7P/:^,I+W_C
MQ@\+WNO6=GJWVO\ Z<?L/VOOU]J_9O\ X*RV?CN^_P""QO@?_A7L-_J5A]H^
M#O\ PSU)H9NOL%G#9VFC?V5:_#S[%C3B-1LO^0M7X S?ZMY##]I3_EK''=>1
M<?9_^?K[7_\ K!KZ)T?]L3]H3PSI?A6VT/XW^*+:V\)XB^&GBB.7^U;[PK_R
MY_9?M?\ R$/P_P <5\[BLO=2L\5]9:7+*/+S6C=OFYFG]I6LGLDVNMUZRQ&U
M/ZM=73O9WTZ7\S^F/]KKX-_LI_&+_@H!_P %%]5\5?"7PS\8-0^ _P"Q)X1^
M-$/V*ZU7^RK+XW>&]-M;/7M+)L[[[!]OU&[NUW:?_>! XKS[2_\ @GW^R3K'
M_!1S]A;X<6GP5T.R\ ?M4?\ !-[Q/\<O&7@N";Q/]AT+X@:1X-_M<6W_ !_\
M_P"G<$'!ST&",_S8_#?]I;X\?#'4/B$G@GXT^(/#=Y\8+7^S_B->>']4\^^U
M[3_^?K[7>].O>O2X?VYOVP+?QAX5^(6H?M)_%#2?$GP_\!ZA\/O"7C2XO[2?
MQ'9_#"\/V2[\&XZ ZCQR>G ^GR;R?,*:2HYU+2]KMROKI>[;T6BMY+5(]E9E
MA>N71Z=/^ ?JY\?/@_\ L3_!OX5_\$Z/VHIOV:= MO!/Q(^*OQ(^%/[0_@?4
M)=>@_M[P?X;\46?AK_A,K7_3N?\ A'?_ &]_+Y6_X*:_LQ_#;]CCXF>.?AUX
M)\*^#]2T3XN>(]'^*OP,\9Z/=ZI/?67P7U?2S>6NEY^W<X-V0/?IGK7RWX#_
M &GIOBEJ7@/X5_MP>//BQX\_9@\+W_B#Q;HW@?P_?VL'B/2-8UCFTU3_ +B-
M]_R%??WKR#X^?%ZY^-GCV;6--UCQIKFB>#-&\/\ P]\):?K&L^1JN@_#?P?I
M?]C^$O[6^V\?\3&Q^R]:]C"9?B_9WJXFZL[K>][-._3KHMT_*YSU)TJ]7VE/
M#::=++;IM^1^U/\ P3WMKQ?^"-__  58^S+>7-A)_P (_P#V-<"VN?W-Q_TZ
M?C_3\?K3]G+]A/\ 8P\4>"_^"<'A[6_V;]/O/$/[7_[+?QH\1>+?%'F^*/\
MB6^,/!^E7=[:71'V[@\]..W%?S>>!OVG/VA_A/\ #_6_@GX#^-OBSP9\-_'$
M6?%O@>WNK6?2KS_K[NOI]>_;BNUT3]NS]L/P_I?@:Y\*_M%?%S04^ ]A<:#X
M)DL[^V^P^#]/O/\ C[M?A[_S^V&HCVX(Z5EB<KQ]5_[+F'U1)MM7:NOJ=DNN
M\M]O*\@]O2H?Q</IWW]?PT/TM^"W[+'[*/Q@_89^-/B'2/ACX3\/?&S]C?XM
M6'_"\[B2_P!>@U7XJ? _1]=O+RTUZT_XGF?MVGWV/#_TLP#BNJ\'_LU_L?\
MA/\ 9(^!7[6WQ:\$ZQ?^#_VE/&_Q(-_XL\'Z-KWBK7/@_P#\(W:_8_AE_9&D
MV=]_H7_'V1JP]LU^&]K\4/B%9V?Q(O\ 0?'VIPP_%B7_ (NA9V>J7-C8^)-0
MO+K^V+NZ\1#_ )_M1^U_\3;'..E=_P""_P!K3]I/X9_#?7_@;\.?C?XP\*_"
MKQI%]OO_  ?X?E^W:'#I_P#R]W5I]NL/]"_I[<XC^Q\P5O99BW]_;7KWUN^C
MUZ"_M'"_]"^WG=H_7WQ1^QG^RIXF_8+UCXS? 'P[X3\<^.?A78>#K_X^^%_B
MY%KW@[XF>&[C6->L]8M/BAX3TG[=_IMCXAL1_P (_I.G]?[)O+^OO+QW^SE^
MSG\=/^"MGP-_9I^(7[.7@^?X,_\ #&]AXIB@T^+7;&>;4/\ A75GXD^T\7V,
M"^N\9QGCGG)/\OTG[1WQXUCP7K?@.]^)?BC_ (1CQ!I>G^'+JSU36;6"#4M.
MT>Z^V:3=7?\ V#KZT TGTZUZ+'^WQ^V>_C#P!X[C_:!^)<?CGX?^$C\*M!\:
M1WUK_P )5IWA<VOV3[+I/_/[8FQS8'^7-9O*,XNG_:,M+]7UM;1:/;K=KI:[
MN+'X;MU6EE]VQ^\/P'_9'_8O^)'P\_81^(,W[+'AVUU;X[_M8_$_]E?QQH\L
M_BC/B_X;>$+K6K*S\5,/MP^Q?$33OL5KM)P"5;GBO)U_87_8C_9]^%_QL^-/
MQ(\#:AXJ^'OAO]MS4/@/JFCZ?H/BGXCWWPW^%^CW7_(4\/>'M%O?[0T7XC?8
M?^8AJ/?O7X[:3^WA^U=X9M_!.E:5^T?\1-*\-^!_B#J&LZ/]GN;6"X\$_$#Q
M)G.O6G/34>?^)ATYZ8S3_#7[;G[9'@?4?BO-HO[0/Q,TW7OBS=7%K\4/[4O]
M+OM*\>'_ (\_[4^R7O\ R^ZC8_\ ,0/XU"R?/KOV>8M[VUD]+W2ULMM-%Y)V
M-L1F&5T+/ZNKV\M[=[?U<_:']DW]CO\ 9%\<?L]_!;XE^*_V>+?XF7GQ,_X*
M&^(/V??#EYXTU37M#OIOV?[RZ/\ 9/BCQ#X>^W?VA9^*].L;NTYU&DTGX3_"
M_P"!_P"QU_P7?MM'^"?A_P 3^(_@_P#M%^&/A5X$N-5T;5+[73\,/^$ILAI'
M]JW=[?$V5AIU]D\'K9XQSFOQ$\-_MJ?M/_#WPKX8\)>$OVA/'GAOP]X+\96_
MC+P;H=O+]H@_X61>77^B:I]K''_/W^M36_[9'[2'AMOC3>?\+O\ B@C_ !\N
MOM7Q^CM[^UO['Q5XQO.?M7V3_P#5]*'D>:5+>UQ334E+233=G>SUO9]=DUN3
MA\92KTG4I8=6_+4_0C_@@9:I'_P5)^&NI167]IZI<?#CXH2ZKJ&C_O['3?\
MBE_^/7/M_7BO@_XC?"OQ5XP_:,_:*U7_ (16\UO1/#?Q:N/B#\0;CQ!I]U!8
M6?A^S\>6=G_97VOU^PW?_P!;U\B^$/QP^*G[.^O_ /">? WXE^)/A7XJU6UN
M-!T?Q)X3U2T_X2JTU"\)^UB[M/3\.?:NM\7?M??M/^*O"?B3PCXG^-GQ(O\
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MZR7TSZ\_C]>]&+C_ )[VG_DI_P#%5[3_ ,,__$+_ * ]Q_X(M2_^0:/^&?\
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MR36>^//_ "U]_P#/\OK*//C:Y>#4K=[;4+K^U+^WN(K7^U9KB\M?L?\ 9?\
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M( RV./7J">_'/%?T)2(LMW(LB(RE[;J#G_CY!Y['^G->C7Q5=8;#VJ5/M_\
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MF0",L*/;8C_GY4_\&U/_ )(/98?^2G_X##_(V/\ A!? O_0E>$/_  1Z)_\
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MS;/7G)!ST-9JO37_ "Y;VZ>G8]!4_P#I_;UM]VQ_(9I?QI^,MW_P27_X(0^
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M8>([*[NAXK.HY_M4D =@9^L4O^@=_<P^KK_H)7H??/P>^)GA+XS?"SP!\6O
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MRW_AY1^Q)_T==\%?_!T/\_\ ZC[9_P L'_A:/Q#_ .@S>?\ ?E:/^%H_$/\
MZ#-Y_P!^5H_XA;A_^ABO_ 8_Y!_KOC_^?"/]4#_AY/\ L2?]'7?!?_P<#_'_
M #@^V6_\/*/V)/\ HZ[X*_\ @Z'^?_U'VS_E@_\ "T?B'_T&;S_ORM'_  M'
MXA_]!F\_[\K5_P#$+\+_ -#%_P#@$/\ (/\ 7?'_ //A'^I]_P /*/V)/^CK
MO@K_ .#H?Y__ %'VR[_AY/\ L2?]'7?!?_P<#_'_ #@^V?\ *_\ ^%H_$/\
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M?]^5KB_XA;A_^AE_Y+'_ "-WQQC_ /H'74_U/?\ AY3^Q+_T=;\&/_!U<_\
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ME<:]:Z/H]_:^'-*O-8L[7[9=Z#I.K:UD?;OL/_ZS7]+_ /P4!_9]\._M!_\
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MG\IWPH_9O^*_Q^\/_%KQ5\$_!EYXST'X,:#K'Q!^(VH1ZS:P0:#X/T?[8?\
M0^/]-_L[''?%>%+<Z5&TVI)<^=H^H:K<_P!EQBZ^W3V>G7EK9_9+6[M++I_I
MWVOT_"OZD_V-K;]GRX/_  4DU7]FOP-\3_!]M<?\$HO$-K\2_#_BCP'=>#K'
M0?BQHPO='\0VH\/7M]R=1-G=>(#[7A(]*/@O^R_^QOXP;_@ESX/F_9R\!W.E
M?M@?L>>*/$?Q>\87<.J?VKX5U?PUI5W9Z3XRM,G&C'3K_//']JYZ<9K:GQ]B
MOK;PV.PSLGNHO^6^NGW675;[EU,CG"G?3YVOO;??\=#^6F:W>U_<WMS]IO\
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M4?M@7$%]^U=^T)80_P#$DTW3/V@O'/@W2[?PWH-K!I6CZ/9^*+S1[2UM.?\
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M>:GK+_WZ_P#K5D!+147FIZR_]^O_ *U'FIZR_P#?K_ZU $M%1>:GK+_WZ_\
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M_2/ZIOVG/CY\'_'7[-'[9/AN']H?P'JOB?QC^W]X0^*OPODU#Q1Y^N6?P_\
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M -^O_K4>:GK+_P!^O_K4<]3L_N9'U>GY?C_D2T5%YJ>LO_?K_P"M1YJ>LO\
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M0 ?9X?\ GFOZ_P"-'V>'_GFOZ_XT44 'V>'_ )YK^O\ C1]GA_YYK^O^-%%
M!]GA_P">:_K_ (T?9X?^>:_K_C110 ?9X?\ GFOZ_P"-+Y$/_/-/^^1116^'
MU6NNGZ(TI]?E^H>1#_SS3_OD5!Y47]Q?RHHKMII:Z+I^IH'E1?W%_*CRHO[B
M_E116@7?=_>_\P\J+^XOY4>5%_<7\J** )OL\/\ SS7]?\:/L\/_ #S7]?\
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1[;MW;[G[WP5_R+UZ/_TH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y 2H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBLW7]/
MNM4T:XL[*_>QN)!\DZ#)4@YII7=F)NR-*N(M]7U!_B[>:4UTYL$L5D6#C:&X
MYK'/C7Q'X+1K3Q7IS7D:J1!?VWW9#V#>A/X'V->?P_$74HO&<GB0VMN99(Q"
M\/.W8.P/KQUKOH8.I)2:LU;0XZN*A&R>FI]'T5Y<NM^*OB&!%HL+:-HS?++>
M2',C^H7_ .M^=>BZ78G3-+MK(W$MP8(PGFRG+/CN:Y*E)T])/7L=,*G/LM"Y
M11161H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %-=TB1GD9511DLQP *:D\,DDD:2HTD9 =5
M8$K]1VKE?B<2/A[JN"1\B]/]X5<(<TU'N3*7+%LYCQOXG@\86TOA?PY9RZG.
M[*SW$?$46#GKW_E7EB>%]:DUMM&73Y?[07EHO0?WL],>]?1GA+3;+3?#.GK9
MVT< DMXW?8N"S%022>]<M:D?\+SON?\ F'+_ $KTL/BO9*4*:T2;^9P5L/[1
MQE-ZLK>!_%EEX=L[?PMKMO+I=[;Y"O/_ *N4DDY#=NOTKTQ'61 Z,&4C((.0
M:P/&NE6&I>%M1-Y:Q3-#;221LR\HP4D$'M53X:$M\/=()))\H]3_ +1KCJ\M
M2+JK1WU.JG>#]F]CK**KO?VB7L=DUS$+J12R0EAN8#J0*L5S69O<**;O3=MW
M+N],TN]=VW<,^F:+!<6BD9E7[S ?4TM !1110 44UG1/O,H^IH$B%=P92/7-
M%A70ZBD!##(((]J6@84444 %%%% !113=ZEMH8;O3- #J*:'5B0&!(Z@&G4
M%%-#J<@,"1UP:4NH.TL ?3- "T4BLK?=8'Z&EH **** "BBFAU8D*P)'7!H
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E-%% $/V:'=NV#-2@8&!2T4 -**QR1S3J** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
